<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="pmc-domain-id">3286</journal-id><journal-id journal-id-type="pmc-domain">vetsciences</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474325</article-id><article-id pub-id-type="pmcid-ver">PMC12474325.1</article-id><article-id pub-id-type="pmcaid">12474325</article-id><article-id pub-id-type="pmcaiid">12474325</article-id><article-id pub-id-type="pmid">41012772</article-id><article-id pub-id-type="doi">10.3390/vetsci12090847</article-id><article-id pub-id-type="publisher-id">vetsci-12-00847</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Evaluation of the Dual Antiviral and Immunomodulatory Effects of <italic toggle="yes">Phallus indusiatus</italic> in a Feline Infectious Peritonitis Model Using PBMCs</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4387-3026</contrib-id><name name-style="western"><surname>Hlaoperm</surname><given-names initials="C">Chularat</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vetsci-12-00847" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00847" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-1277-2590</contrib-id><name name-style="western"><surname>Moyadee</surname><given-names initials="W">Wassamon</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-vetsci-12-00847" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00847" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wongsaengnoi</surname><given-names initials="E">Emwalee</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af3-vetsci-12-00847" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Klankaew</surname><given-names initials="W">Wiwat</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af4-vetsci-12-00847" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rattanasrisomporn</surname><given-names initials="A">Amonpun</given-names></name><xref rid="af5-vetsci-12-00847" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Paemanee</surname><given-names initials="A">Atchara</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af6-vetsci-12-00847" ref-type="aff">6</xref><xref rid="af7-vetsci-12-00847" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2421-7859</contrib-id><name name-style="western"><surname>Choowongkomon</surname><given-names initials="K">Kiattawee</given-names></name><xref rid="af4-vetsci-12-00847" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4291-4308</contrib-id><name name-style="western"><surname>Rungsuriyawiboon</surname><given-names initials="O">Oumaporn</given-names></name><xref rid="af3-vetsci-12-00847" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2426-0961</contrib-id><name name-style="western"><surname>Rattanasrisomporn</surname><given-names initials="J">Jatuporn</given-names></name><xref rid="af1-vetsci-12-00847" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00847" ref-type="aff">2</xref><xref rid="c1-vetsci-12-00847" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Zhou</surname><given-names initials="Z">Ziyao</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Zhong</surname><given-names initials="Z">Zhijun</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00847"><label>1</label>Graduate Program in Animal Health and Biomedical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand; <email>chularat.h@ku.th</email> (C.H.); <email>wassamon.moy@ku.th</email> (W.M.)</aff><aff id="af2-vetsci-12-00847"><label>2</label>Department of Companion Animal Clinical Sciences, Faculty of Veterinary Medicine, Kasetsart University, Bangkok 10900, Thailand</aff><aff id="af3-vetsci-12-00847"><label>3</label>Department of Veterinary Technology, Faculty of Veterinary Technology, Kasetsart University, Bangkok 10900, Thailand; <email>emwalee.wo@ku.th</email> (E.W.); <email>cvtopr@ku.ac.th</email> (O.R.)</aff><aff id="af4-vetsci-12-00847"><label>4</label>Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand; <email>wiwat.klankaew@gmail.com</email> (W.K.); <email>fsciktc@ku.ac.th</email> (K.C.)</aff><aff id="af5-vetsci-12-00847"><label>5</label>Interdisciplinary of Genetic Engineering and Bioinformatics, Graduate School, Kasetsart University, Bangkok 10900, Thailand; <email>fgraapr@ku.ac.th</email></aff><aff id="af6-vetsci-12-00847"><label>6</label>National Omics Center, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Luang, Pathum Thani 12120, Thailand; <email>atchara.pae@biotec.or.th</email></aff><aff id="af7-vetsci-12-00847"><label>7</label>Food Biotechnology Research Team, Functional Ingredients and Food Innovation Research Group, National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), Khlong Luang, Pathum Thani 12120, Thailand</aff><author-notes><corresp id="c1-vetsci-12-00847"><label>*</label>Correspondence: <email>fvetjpn@ku.ac.th</email></corresp></author-notes><pub-date pub-type="epub"><day>01</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>12</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497675</issue-id><elocation-id>847</elocation-id><history><date date-type="received"><day>29</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="vetsci-12-00847.pdf"/><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>This study explores the potential of <italic toggle="yes">Phallus indusiatus</italic> (<italic toggle="yes">P. indusiatus</italic>), a medicinal mushroom, as a dual-action treatment for feline infectious peritonitis (FIP), a fatal disease caused by feline coronavirus. <italic toggle="yes">P. indusiatus</italic> demonstrated the most pronounced inhibitory effect among the 17 mushroom extracts tested (69.2% inhibition of FIPV M<sup>pro</sup>), showing a level of activity approaching that of standard antivirals such as lopinavir and ritonavir. The extract also significantly reduced nitric oxide production (a marker of inflammation) in lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs) from healthy cats, indicating anti-inflammatory effects. However, immune cells from cats already suffering from FIP, which were in a chronically inflamed state, did not respond to the extract or to dexamethasone. This highlights the complexity of FIP-related inflammation. This study also successfully cultured PBMCs from FIP fluid for the first time, providing a novel in vitro model for future research. Overall, the results suggest that <italic toggle="yes">P. indusiatus</italic> has promising antiviral and anti-inflammatory properties, though further research is needed to isolate active compounds and test in live infection models.</p></abstract><abstract><title>Abstract</title><p>Feline infectious peritonitis (FIP) is a progressive and often fatal disease caused by a virulent biotype of feline coronavirus (FCoV). Although antiviral treatments are now available, relapse and resistance remain ongoing concerns. This study investigates the therapeutic potential of <italic toggle="yes">P. indusiatus</italic>, a medicinal mushroom, for its antiviral and anti-inflammatory activities against FIP. The main protease (FIPV M<sup>pro</sup>) of feline infectious peritonitis virus (FIPV) was recombinantly expressed and purified to facilitate enzyme inhibition screening. <italic toggle="yes">P. indusiatus</italic> exhibited the strongest FIPV M<sup>pro</sup> inhibitory activity among the 17 mushroom extracts tested (69.2%), showing a notable level of inhibition relative to standard antiviral agents such as lopinavir and ritonavir. To assess its anti-inflammatory potential, PBMCs derived from healthy cats and FIP-associated effusions (FIP fluid) were cultured and stimulated with LPS to induce inflammation. In healthy PBMCs, <italic toggle="yes">P. indusiatus</italic> significantly reduced nitrite levels, with effects similar to dexamethasone. However, PBMCs from FIP fluid, already in an activated state, showed no additional response. Notably, this study is the first to successfully isolate and culture PBMCs from FIP fluid, providing a new platform for future immunological research. These findings suggest that <italic toggle="yes">P. indusiatus</italic> possesses both antiviral and anti-inflammatory properties, positioning it as a potential dual-action therapeutic candidate for FIP. Further investigation into cytokine signaling pathways is warranted to clarify its mechanisms of action and advance future therapeutic development.</p></abstract><kwd-group><kwd><italic toggle="yes">Phallus indusiatus</italic></kwd><kwd>PBMCs</kwd><kwd>feline coronavirus (FCoV)</kwd><kwd>feline infectious peritonitis (FIP)</kwd><kwd>FIPV protease</kwd><kwd>FIPV M<sup>pro</sup></kwd><kwd>antiviral</kwd><kwd>anti-inflammatory</kwd></kwd-group><funding-group><award-group><funding-source>Kasetsart University Research and Development Institute (KURDI)</funding-source><award-id>FF(KU) 7.68</award-id></award-group><award-group><funding-source>The Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand</funding-source></award-group><funding-statement>This research is funded by the High-Quality Research Graduate Development Cooperation Project between Kasetsart University and the National Science and Technology Development Agency (NSTDA), Kasetsart University Research and Development Institute (KURDI), grant number FF(KU) 7.68 and The Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00847"><title>1. Introduction</title><p>Feline coronavirus (FCoV) is an enveloped, positive-sense single-stranded RNA virus in the Coronaviridae family commonly found in domestic cats [<xref rid="B1-vetsci-12-00847" ref-type="bibr">1</xref>]. It exists in two biotypes: feline enteric coronavirus (FECV) [<xref rid="B2-vetsci-12-00847" ref-type="bibr">2</xref>], which typically causes mild gastrointestinal signs and is often self-limiting in immunocompetent cats, and feline infectious peritonitis virus (FIPV), the pathogenic variant responsible for feline infectious peritonitis (FIP) [<xref rid="B3-vetsci-12-00847" ref-type="bibr">3</xref>]. First reported in 1966, FIP is fatal, immune-mediated disease that primarily affects kittens, adolescents, and young adult cats, and remains a significant cause of mortality in this population [<xref rid="B4-vetsci-12-00847" ref-type="bibr">4</xref>]. Approximately 12% of FCoV-infected cats progress to FIP, with environmental stress and immune dysfunction as a key contributing factors [<xref rid="B5-vetsci-12-00847" ref-type="bibr">5</xref>]. Although antiviral drugs have recently become available, delayed diagnosis still results in high mortality, emphasizing the need for timely and accurate detection [<xref rid="B6-vetsci-12-00847" ref-type="bibr">6</xref>]. Pathogenesis involves efficient replication of FCoV in activated monocytes and macrophages, leading to systemic inflammation, pyogranulomatous lesions, and T-cell depletion [<xref rid="B6-vetsci-12-00847" ref-type="bibr">6</xref>,<xref rid="B7-vetsci-12-00847" ref-type="bibr">7</xref>]. Altered cytokine profiles, including elevated interleukin (IL)-1&#946;, IL-6, IL-10, IL-12p40, and tumor necrosis factor-alpha (TNF-&#945;), have been identified in affected cats, indicating that immune dysregulation plays a key role in the advancement of FIP [<xref rid="B8-vetsci-12-00847" ref-type="bibr">8</xref>].</p><p>Edible mushrooms have been reported to possess multiple biomedical properties, including antiviral, anti-inflammatory activities, and immunomodulatory effects through cytokine stimulation [<xref rid="B7-vetsci-12-00847" ref-type="bibr">7</xref>,<xref rid="B8-vetsci-12-00847" ref-type="bibr">8</xref>]. These effects are largely attributed to bioactive compounds such as polysaccharides, terpenoids, and alkaloids. These compounds enhance phagocytic activity, increase IL-1&#946; and TNF-&#945; expression, and activate key signaling pathways such as ERK1/2, JNK, and p38 MAPKs. They also promote NF-&#954;B p65 phosphorylation and nuclear translocation and can bind to macrophages via Toll-like receptor 4 (TLR4) [<xref rid="B8-vetsci-12-00847" ref-type="bibr">8</xref>]. Certain mushrooms may also help alleviate clinical signs associated with cytokine storms. While some compounds have shown antiviral activity, scientific evaluation in feline models remains limited.</p><p>In the preliminary inflammation model of this study, both lipopolysaccharide (LPS) and FIPV (or viruses in general) are potent activators of the NF-&#954;B and AP-1 signaling pathways [<xref rid="B9-vetsci-12-00847" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00847" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00847" ref-type="bibr">11</xref>]. These pathways function as central molecular &#8220;switches&#8221; that regulate the transcription of various inflammatory mediators, including NO, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2), and the pro-inflammatory cytokines (e.g., TNF-&#945;, IL-6, and IL-1&#946;) [<xref rid="B12-vetsci-12-00847" ref-type="bibr">12</xref>,<xref rid="B13-vetsci-12-00847" ref-type="bibr">13</xref>]. Therefore, using LPS as an inflammatory stimulant in PBMCs to investigate the anti-inflammatory effects of mushroom extracts is well justified as a preliminary inflammation model, as it activates shared pathways involved in cytokine and iNOS expression mechanisms that are also triggered by FIPV (<xref rid="vetsci-12-00847-f001" ref-type="fig">Figure 1</xref>).</p><p>Coronaviruses are RNA viruses that hijack the host&#8217;s translational machinery to generate viral proteins. The resulting polyproteins must be cleaved to release individual functional proteins necessary for viral replication and transcription. The virus encodes proteases, including the main protease (M<sup>pro</sup>), also known as 3CLpro, which has conserved sequences that facilitate the assembly of the viral replicase complex [<xref rid="B14-vetsci-12-00847" ref-type="bibr">14</xref>]. The M<sup>pro</sup> protein of FCoV is essential for the replication cycle, as observed in other members of the Coronaviridae family [<xref rid="B15-vetsci-12-00847" ref-type="bibr">15</xref>]. Therefore, FIPV M<sup>pro</sup> protein is considered a prominent drug target for antiviral therapy against FIP (e.g., GC376) [<xref rid="B14-vetsci-12-00847" ref-type="bibr">14</xref>,<xref rid="B16-vetsci-12-00847" ref-type="bibr">16</xref>].</p><p>The immune system plays a crucial role in controlling viral infections, including the suppression of FCoV replication and prevention of progression to FIP. In this study, 17 mushroom extracts were screened as potential candidates for alternative immunomodulatory strategies in cats. Screening was conducted to assess antiviral activity by them against FIPV M<sup>pro</sup> to identify active compounds. The extract with the strongest inhibitory effect was selected for further assessment of its anti-inflammatory potential. PBMCs were isolated from both healthy cats and cats with FIP-associated effusions, including pleural, peritoneal, or a combination of both, and were cultured under optimized conditions. These PBMCs were then stimulated with LPS and treated with the selected extract to assess nitrite-scavenging activity. The resulting data will serve as a foundation for future investigations into cytokine modulation, particularly in the context of FIP-related inflammation and antiviral response.</p></sec><sec id="sec2-vetsci-12-00847"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00847"><title>2.1. Ethics Statement</title><p>This study was approved by the Institutional Animal Care and Use Committee of Kasetsart University, Bangkok, Thailand, under protocol number ACKU67-VET-124. Additionally, all sample collections were performed with the informed consent of the cat owners.</p></sec><sec id="sec2dot2-vetsci-12-00847"><title>2.2. Protein Expression and Purification</title><p>The expression and purification of FIPV&#8217;s main protease in this study, called &#8220;FIPV M<sup>pro</sup>&#8221;, have been described previously [<xref rid="B17-vetsci-12-00847" ref-type="bibr">17</xref>]. In this study, the FIPV M<sup>pro</sup> was derived from the FIPV WSU-79-1146 strain. The coding sequence for M<sup>pro</sup> included an N-terminal 10xHis tag and a TEV cleavage site, resulting in a recombinant protein with an approximate molecular weight of 37.2 kDa. The gene was synthesized into the pGEX-4T-1 vector (GenScript, USA) and transformed into <italic toggle="yes">Escherichia coli</italic> strain BL21(DE3) for protein expression. Cultures were grown in LB medium incubated at 37 &#176;C for 3 to 4 h, the absorbance was measured at OD 600 to 0.8, and then the sample was induced by 0.4 mM isopropyl-&#946;-d-thiogalactopyranoside at 37 &#176;C for 18&#8211;20 h. The FIPV M<sup>pro</sup> was purified by Ni<sup>2+</sup> affinity column (Cytiva AB, Sweden). Western blotting was performed to confirm the protein expression, using an anti-His tag primary antibody (Thermo Fisher Scientific, USA) and an HRP-conjugated Goat Anti-Mouse IgG secondary antibody (Thermo Fisher Scientific, USA) for signal detection.</p></sec><sec id="sec2dot3-vetsci-12-00847"><title>2.3. Inhibition of FIPV M<sup>pro</sup> Protease</title><p>The FIPV M<sup>pro</sup> modified with Dabcyl-KTSAVLQSGFRKM-E (Edans) (Genscript USA, Piscataway, NJ, USA) was prepared in a buffer containing 20 mM Tris (pH 7.5), 100 mM NaCl, 2 mM DTT, and 0.05 mM EDTA. The enzyme activity was subsequently examined in a 384-well plate containing 1 &#181;M FIPV M<sup>pro</sup> in buffer solution. Subsequently, enzyme activity inhibitors, including lopinavir and itonavir as positive controls, were added for comparison with 10 &#181;g/mL mushroom extracts. The final inhibitor concentration in the reaction was set to 10 &#181;g/mL. The reaction was initiated by adding the substrate at a final concentration of 40 &#181;M. The increase in fluorescence intensity of the substrate at 340 nm was measured to determine the relationship between Relative Fluorescence Units (RFUs) per second, using a microplate reader (Infinite 200, Tecan Group Ltd., M&#228;nnedorf, Switzerland) and GraphPad version 8.0 software, as described in Equation (1).<disp-formula id="FD1-vetsci-12-00847"><label>(1)</label><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mo mathvariant="normal">%</mml:mo><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">Relative inhibition</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">z</mml:mi><mml:mo>&#8722;</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">I</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mo>&#215;</mml:mo><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">V</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>&#160;</mml:mo><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">z</mml:mi></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>V<sub>0</sub> represents the initial reaction velocity of the enzyme. It indicates how fast the enzyme converts substrate to product at the start of the reaction. V<sub>0</sub> enz is the initial reaction velocity of the enzyme without an inhibitor. V<sub>0</sub> Inhibitor is the initial reaction velocity of the enzyme in the presence of an inhibitor.</p><p>Given the constraints associated with cell culture systems and the limited availability of animal-derived samples, particularly those obtained from experimental models, this phase of the study was designed to reduce animal usage by utilizing an in vitro screening approach. This model was employed to identify mushroom extracts exhibiting the highest inhibitory activity against the FIPV M<sup>pro</sup>. The extract demonstrating the most potent inhibitory effect will be selected for further investigation of its anti-inflammatory properties.</p></sec><sec id="sec2dot4-vetsci-12-00847"><title>2.4. Animals and Experimental Design</title><p>This research was approved for sample collection from the Kasetsart University Veterinary Teaching Hospital in Bangkok, Thailand. PBMCs were isolated from healthy donor cats (<italic toggle="yes">n</italic> = 20). In parallel, pleural and/or ascitic fluid samples were collected from cats clinically diagnosed with effusive FIP, based on a combination of consistent clinical, laboratory, and imaging findings. These included serum biochemical and hematological abnormalities, clinical signs such as anorexia, depression, intermittent fever, abdominal distension, or dyspnea due to pleural effusion. Radiographic or ultrasonographic imaging confirmed the presence of fluid accumulation in body cavities and involvement of internal organs. Fluid analysis and cytology revealed pyogranulomatous inflammation, with a proteinaceous, granular background, and a cell population consisting of macrophages, non-degenerate neutrophils, and few lymphocytes. The effusions were classified as modified transudates or non-septic exudates. The diagnosis was further supported by additional findings, including a serum albumin-to-globulin (A:G) ratio of less than 0.8, a positive Rivalta&#8217;s test, and/or a positive PCR result for FCoV, in accordance with previously published criteria [<xref rid="B18-vetsci-12-00847" ref-type="bibr">18</xref>,<xref rid="B19-vetsci-12-00847" ref-type="bibr">19</xref>]. The pleural and/or ascitic fluid samples were subsequently used for mononuclear cell isolation. These samples (<italic toggle="yes">n</italic> = 20) were subsequently used for mononuclear cell isolation. For simplicity, mononuclear cells isolated from effusions are referred to as &#8220;PBMCs from FIP fluid&#8221; throughout this study. The sample size was derived from data in other similar studies. All analyses were performed using GraphPad Prism version 9 (GraphPad Software, LLC, Boston, MA, USA) [<xref rid="B20-vetsci-12-00847" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot5-vetsci-12-00847"><title>2.5. The Preparation of the Mushroom Extraction Procedure</title><p>A total of 17 types of medical mushrooms were selected, including <italic toggle="yes">Pleurotus ostreatus</italic>, <italic toggle="yes">Flammulina filiformis</italic>, <italic toggle="yes">Agrocybe cylindracea</italic>, <italic toggle="yes">Lentinula edodes</italic>, <italic toggle="yes">Tuber Uncinatum</italic>, <italic toggle="yes">Lignosus rhinocerotis</italic>, <italic toggle="yes">Volvariella volvacea</italic>, <italic toggle="yes">Ganoderma oregonense</italic>, <italic toggle="yes">Ganoderma formosanum</italic>, <italic toggle="yes">Ganoderma lucidum</italic>, <italic toggle="yes">Inonotus obliquus</italic>, <italic toggle="yes">Hericium erinaceus</italic>, <italic toggle="yes">Psilocybe cubensis</italic>, <italic toggle="yes">Phellinus igniarius</italic>, <italic toggle="yes">Dasoclema simensis</italic>, <italic toggle="yes">Pleurotus ostreatus,</italic> and <italic toggle="yes">Phallus indusiatus</italic>. A dry sample of 100 g was air-dried and grinded by mixer grinder, immersed in 95% ethyl alcohol (ethanol) 200 mL at a temperature of 37 &#176;C, and shaken for 12 h. Afterward, the liquid part was separated and the ethanol was evaporated using a rotary evaporator under vacuum. The crude extract was stored at a temperature of &#8722;20 &#176;C until analysis. The extracts from the 17 types of mushrooms will be further tested for their FIPV M<sup>pro</sup> inhibitory activity. In this study, crude extracts were prepared using the same stock and extraction protocol described by Theeraraksakul, K. et al., 2023 [<xref rid="B21-vetsci-12-00847" ref-type="bibr">21</xref>].</p></sec><sec id="sec2dot6-vetsci-12-00847"><title>2.6. Preparation of PBMCs</title><p>Whole blood from healthy donor cats and effusion samples (pleural, ascitic, or both) from FIP cats were processed to isolate PBMCs by separating the buffy coats using centrifugation with Lymphoprep&#8482; (Corning<sup>&#174;</sup>, USA) at 600 g for 30 min to isolate PBMCs. Subsequently, complete RPMI-1640 medium (Corning<sup>&#174;</sup>, USA) containing 10% fetal bovine serum (FBS; Gibco<sup>&#174;</sup>, USA) and 1% penicillin&#8211;streptomycin (Gibco<sup>&#174;</sup>, USA) was added, and the cell concentration was adjusted to 1 &#215; 10<sup>6</sup> cells/mL. The cells were counted, and their viability was assessed by mixing the separated cells with a 0.4% Trypan Blue solution (Gibco<sup>&#174;</sup>, USA) in a 1:1 ratio. A hemocytometer was used to count the cells under a microscope.</p><p>In the case of isolating PBMCs from effusion samples, referred to in this study as &#8220;PBMCs from FIP fluid&#8221; the sample characteristics of the FIP fluid were carefully considered. If the sample exhibited high viscosity, it was diluted with 1&#215; phosphate-buffered saline (PBS; Cytiva HyClone&#8482;, USA) to facilitate efficient cell pelleting. The diluted sample was then centrifuged at 600&#215; <italic toggle="yes">g</italic> for 10 min. The supernatant was discarded, and the cell pellet was retained. The pellet was subsequently washed three times with RPMI medium at a 1:1 ratio, each wash involving centrifugation at 600&#215; <italic toggle="yes">g</italic> for 10 min. Once the cells were isolated, cell counting was performed, and the cells were cultured under the same conditions as previously described.</p></sec><sec id="sec2dot7-vetsci-12-00847"><title>2.7. In Vitro Optimize Toxicity of P. indusiatus, LPS, and DMSO</title><p>The toxicity of <italic toggle="yes">P. indusiatus</italic> extract at concentrations of 10,000, 5000, 2500, 625, 156, 78, 39, and 19 &#181;g/mL was tested on PBMCs isolated from the whole blood of donor cats. PBMCs (1 &#215; 10<sup>6</sup> cells/mL) were seeded into a 96-well plate and pre-incubated for 1&#8211;2 h in a humidified atmosphere with 5% CO<sub>2</sub> at 37 &#176;C. Subsequently, the cells were treated with various concentrations of <italic toggle="yes">P. indusiatus</italic> extract dissolved in 0.5% DMSO. The PBMCs were incubated for 24 h. Following treatment, cell viability was assessed using the Cell Counting Kit-8 (CCK-8) colorimetric assay (Dojindo, Kumamoto, Japan). Briefly, 10 &#181;L of CCK-8 solution was added to each well and incubated for 2&#8211;4 h. The absorbance of each well was then measured at 450 nm using a microplate reader (EnSight<sup>&#174;</sup> Multimode Plate Reader, PerkinElmer, Waltham, MA, USA). Cell viability was determined by calculating the percentage of absorbance relative to the control group (non-treated PBMCs).</p><p>The testing involved determining optimal concentrations and exposure times in generating PBMCs after stimulation with LPS (Sigma-Aldrich<sup>&#174;</sup>, Israel) at various concentrations (0.001, 0.01, 0.1, and 1 &#181;g/mL). Additionally, testing was conducted to determine suitable concentrations for cell viability using dimethyl sulfoxide (DMSO, Uvasol, Japan) at concentrations of 0.5%, 1%, 1.5%, and 2%, compared to a control group without DMSO. Cell viability was assessed using the CCK-8 colorimetric assay (Dojindo, Kumamoto, Japan) under the same conditions as described previously.</p></sec><sec id="sec2dot8-vetsci-12-00847"><title>2.8. Anti-Inflammatory Assay Using Nitrite Scavenging Activity</title><p>To determine the effect of <italic toggle="yes">P. indusiatus</italic> extract on nitrite production, a primary breakdown product of nitric oxide, cells were suspended in a 96-well plate containing complete RPMI-1640 medium and pre-incubated for 1&#8211;2 h in a humidified atmosphere with 5% CO<sub>2</sub> at 37 &#176;C. Subsequently, the cells were treated with <italic toggle="yes">P. indusiatus</italic> at a concentration of 19 &#181;g/mL and dexamethasone at 5 &#181;g/mL as a positive drug control in the presence of LPS (1 &#181;g/mL) and incubated for 24 h. Nitrite production was determined by calculating the percentage of absorbance relative to the control group (non-treated PBMCs) using the Griess Reagent System (Promega, USA). A parallel test was conducted on PBMCs isolated from FIP fluid under the same conditions, but without LPS stimulation. This study investigates the potential effects of <italic toggle="yes">P. indusiatus</italic> extract on inflammation in PBMCs isolated from whole blood and fluid samples of cats diagnosed with FIP. The primary aim was to evaluate whether the extract can modulate inflammation by measuring nitrite concentrations, which is a marker of inflammatory response.</p></sec><sec id="sec2dot9-vetsci-12-00847"><title>2.9. Statistical Analysis</title><p>Data are presented as mean &#177; Standard Error of the Mean (SEM), with each experiment replicated at least twice to ensure reliability. PBMC viability from whole blood and FIP fluid was compared using two-way ANOVA, with comparisons made between cell means within each row (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">n</italic> = 5). The effect of varying LPS concentrations (0.001, 0.01, 0.1, and 1 &#181;g/mL) on nitrite levels was assessed after 24 h using one-way ANOVA, compared to a no-LPS control (<italic toggle="yes">p</italic> &lt; 0.05). The impact of 19 &#181;g/mL <italic toggle="yes">P. indusiatus</italic> and 5 &#181;g/mL dexamethasone on nitrite production in PBMCs from donor cat whole blood was evaluated after 24 h, with data shown as mean &#177; SEM (<italic toggle="yes">n</italic> = 8), comparing column means. Inflammation modulation in PBMCs from FIP fluid treated with <italic toggle="yes">P. indusiatus</italic> extract (<italic toggle="yes">n</italic> = 5) was analyzed using one-way ANOVA (<italic toggle="yes">p</italic> &lt; 0.05). Differences in treatment responses between PBMCs from whole blood and FIP fluid were assessed by two-way ANOVA (<italic toggle="yes">p</italic> &lt; 0.05, <italic toggle="yes">n</italic> = 4).</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00847"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00847"><title>3.1. Expression and Purification of FIPV M<sup>pro</sup></title><p>Recombinant His-tagged FIPV 3CLpro, expressed in <italic toggle="yes">E. coli</italic> BL21 (DE3), was purified using a Ni<sup>2+</sup> affinity column. The expression of the FIPV M<sup>pro</sup> or FIPV-3C-like Protease, (3CL<sup>pro</sup>), was induced with 0.4 mM isopropyl &#946;-d-1-thiogalactopyranoside (IPTG), followed by incubation for 18&#8211;24 h. Quantitative analysis using SDS-PAGE confirmed the expression of the FIPV M<sup>pro</sup> protein with a molecular weight of 37.20 kDa (<xref rid="vetsci-12-00847-f002" ref-type="fig">Figure 2</xref>A).</p><p>Qualitative analysis was performed using the Western blot technique, which utilized the specificity of the primary antibody (Anti-His Tag (HRP)) for proteins labeled with a 6x His-Tag. A secondary antibody (Goat Anti-Mouse IgG (HRP)) was employed to bind with HRP substrates. This revealed a band corresponding to the FIPV M<sup>pro</sup> protein at a size of 37.20 kDa (<xref rid="vetsci-12-00847-f002" ref-type="fig">Figure 2</xref>B). The results of determining the optimal concentration of FIPV M<sup>pro</sup> enzymatic activity, using Dabcyl-KTSAVLQSGFRKM-E (Edans) as the substrate at a final concentration of 40 &#181;M, showed that the reaction rate (or fluorescence intensity) of the substrate increased as the enzyme concentration was raised to 0.5 and 1 &#181;M, separately (<xref rid="vetsci-12-00847-f002" ref-type="fig">Figure 2</xref>C).</p></sec><sec id="sec3dot2-vetsci-12-00847"><title>3.2. Inhibition of FIPV M<sup>pro</sup> Activity by Antiviral Drugs and Crude Mushroom Extract</title><p>The effect of various inhibitors on FIPV M<sup>pro</sup> activity at a concentration of 1 &#181;M was evaluated using protease inhibitors or antiviral drugs, with lopinavir and ritonavir (National Cancer Institute (NCI, USA)) serving as positive controls for comparison with mushroom extracts. Lopinavir and ritonavir were used at final concentrations of 10 and 100 &#181;g/mL to assess enzyme inhibition by monitoring the reaction rate. This was performed by measuring the fluorescence intensity over 30 min. The initial reaction rate (V<sub>0</sub>) was then used to calculate the percentage of enzyme activity inhibition. At a concentration of 10 &#181;g/mL, lopinavir inhibited enzyme activity by 84.13%, while ritonavir inhibited it by 71.88% (<xref rid="vetsci-12-00847-f003" ref-type="fig">Figure 3</xref>).</p><p>Relative inhibition of the FIPV M<sup>pro</sup> assay was evaluated using crude mushroom extracts. The experimental results showed that <italic toggle="yes">P. indusiatus</italic> exhibited the highest inhibition of FIPV M<sup>pro</sup> activity at 69.2%. Therefore, the extract from <italic toggle="yes">P. indusiatus</italic> was selected for further testing on its anti-inflammatory effects (<xref rid="vetsci-12-00847-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec3dot3-vetsci-12-00847"><title>3.3. Optimization of PBMC Culture Conditions Using Whole Blood Samples and FIP Fluid</title><p>The characteristics of PBMCs isolated from both whole blood of donor cat and FIP fluid revealed that PBMCs from whole blood contained a small number of platelets and red blood cell contamination (<xref rid="vetsci-12-00847-f004" ref-type="fig">Figure 4</xref>A). In contrast, PBMCs isolated from FIP fluid were less pure in terms of white blood cells compared to those from whole blood. The PBMCs sometimes exhibited platelet clumping, which was attributed to the diseased state of the animals. Occasionally, proteins were also present, contributing to the platelet clumping (<xref rid="vetsci-12-00847-f004" ref-type="fig">Figure 4</xref>B). Therefore, for the PBMCs isolated from FIP fluid, samples without platelet clumping will be used (<xref rid="vetsci-12-00847-f004" ref-type="fig">Figure 4</xref>C).</p><p>The experimental results show that at a DMSO concentration of 0.5%, the viability of PBMCs (1 &#215; 10<sup>6</sup> cells/mL) isolated from whole blood and FIP fluid was 93.75 &#177; 2.92% and 90.23 &#177; 2.1%, respectively. This concentration is suitable for further use as a solvent for extracts as it is non-toxic to the cells. However, concentrations of 1%, 1.5%, and 2% were found to be unsuitable as solvents since the viability of PBMCs was below 90%. Therefore, in this study, DMSO at a concentration not exceeding 0.5% was chosen as the solvent for the crude mushroom extract, because PBMCs isolated from both whole blood and FIP fluid had a viability percentage greater than 90% (shown in <xref rid="app1-vetsci-12-00847" ref-type="app">Figure S1</xref>)</p><p>The viability assessment of PBMCs (1 &#215; 10<sup>6</sup> cells/mL) isolated from whole blood and FIP fluid, conducted using the Trypan Blue Exclusion Assay, revealed that on Day 0, cell viability exceeded 90% for both sources, making them suitable for experiments. By Day 1, PBMCs from whole blood remained suitable for experimentation, while PBMCs from FIP fluid were not, as their viability had dropped below 90%. When comparing each day to Day 0, no statistically significant differences were observed from Day 1 to Day 3, whereas statistically significant differences were observed from Day 4 to Day 5.</p><p>A comparison of PBMC viability isolated from both whole blood and FIP fluid was performed using a two-way ANOVA (<italic toggle="yes">p</italic> &lt; 0.05). The results indicated no statistically significant differences in PBMC viability between the two sample types from Day 0 to Day 4. However, on Day 5, a statistically significant difference in PBMC viability was observed between PBMCs isolated from whole blood and FIP fluid (<xref rid="vetsci-12-00847-f005" ref-type="fig">Figure 5</xref>).</p><p>However, in this study, PBMCs isolated from samples will be used for testing within 24 h, as they exhibit the highest cell viability, exceeding 90% [<xref rid="B22-vetsci-12-00847" ref-type="bibr">22</xref>]. This summary confirms that PBMCs isolated from both donor and fluid of FIP retain high viability and are appropriate for subsequent experimental applications.</p></sec><sec id="sec3dot4-vetsci-12-00847"><title>3.4. LPS-Stimulated PBMCs</title><p>PBMCs isolated from donor cat blood samples were stimulated with LPS at concentrations ranging from 1 to 0.001 &#181;g/mL for 24 h. Cell viability and proliferation were then assessed using the CCK-8 colorimetric assay. The results showed that increasing LPS concentrations significantly enhanced cell viability. In the control group without LPS stimulation, cell viability was 91.60 &#177; 0.85%, whereas at the highest LPS concentration (1 &#181;g/mL), cell viability increased to 99.21 &#177; 0.10% (<xref rid="vetsci-12-00847-f006" ref-type="fig">Figure 6</xref>).</p><p>Subsequently, a comparison of PBMCs viability at each concentration with the control group without LPS addition revealed that at a concentration of 0.001 &#181;g/mL, there was no statistically significant difference compared to the control group. However, at concentrations of 0.01, 0.1, and 1 &#181;g/mL, there were statistically significant differences from the control group (<xref rid="vetsci-12-00847-f006" ref-type="fig">Figure 6</xref>). The concentrations of LPS used did not exhibit cytotoxicity, as cell viability exceeded 90% in all cases. Therefore, an LPS concentration of 1 &#181;g/mL was selected to stimulate its effect on inducing cellular inflammation.</p></sec><sec id="sec3dot5-vetsci-12-00847"><title>3.5. Effect of P. indusiatus on the Cell Viability of PBMCs</title><p>The toxicity test of <italic toggle="yes">P. indusiatus</italic> extract at various concentrations on PBMCs derived from the whole blood of donor cats over 24 h was assessed using the CCK-8 colorimetric assay. The results revealed that at concentrations of 10,000, 5000, 2500, 625, 156, 78, and 39 &#181;g/mL, the extract remained toxic to the cells, as cell viability was below 90%. The PBMCs exhibited morphological changes, such as reduced size and loss of sheen, indicating cell death, which was distinct from the control group. However, at a concentration of 19 &#181;g/mL, the cells retained their normal morphology, showing no changes compared to the control group, which is consistent with the 90% viability results. Consequently, a concentration of 19 &#181;g/mL is suitable for further testing. The IC<sub>50</sub> value was calculated to be 1890 &#181;g/mL (as shown in <xref rid="app1-vetsci-12-00847" ref-type="app">Table S1</xref>).</p></sec><sec id="sec3dot6-vetsci-12-00847"><title>3.6. Evaluation of Nitrite Scavenging Activity of P. indusiatus Extract in LPS-Stimulated PBMCs</title><p>The evaluation of nitrite (NO<sub>2</sub><sup>&#8722;</sup>) concentration, resulting from the oxidation of nitric oxide (NO), which serves as an indicator for assessing inflammation in LPS-stimulated cells, revealed statistically significant differences compared to the control group at LPS concentrations of 1, 0.1, 0.01, and 0.001 &#181;g/mL (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>A). The nitrite production measured showed a concentration of 7.7 &#181;M, indicating the induction of inflammation in PBMC stimulated with LPS at the respective concentrations. However, considering the viability of PBMCs, it was found that at a concentration of 1 &#181;g/mL, the cells exhibited the highest viability, consistent with the cell viability results assessed using the CCK-8 assay, which showed 99.21 &#177; 0.01% (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>A). Therefore, an LPS concentration of 1 &#181;g/mL was selected for inducing inflammation in PBMCs.</p><p>The test results showed that PBMCs stimulated with 1 &#181;g/mL LPS (negative control) released a nitrite concentration of 19.73 &#181;M. In contrast, the group treated with the anti-inflammatory drug dexamethasone at 5 &#181;g/mL (positive control) exhibited a reduced nitrite concentration of 12.56 &#181;M. Moreover, the group treated with 19 &#181;g/mL of <italic toggle="yes">P. indusiatus</italic> mushroom extract demonstrated a further reduction in nitrite concentration to 13.36 &#181;M. These results suggest that the <italic toggle="yes">P. indusiatus</italic> mushroom extract may have potential anti-inflammatory properties (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>B).</p><p>The results also showed that PBMCs isolated from FIP fluid exhibited inflammation, as assessed by the nitrite concentration shown in <xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>C, which measured 15.87 &#181;M without stimulation by LPS. This indicates that the cat with FIP already had inflammation in its PBMCs. In the group treated with the anti-inflammatory drug dexamethasone (positive control), the nitrite concentration was 16.13 &#181;M, which was not statistically different from the control group. Similarly, the test group treated with <italic toggle="yes">P. indusiatus</italic> extract had a nitrite concentration of 16.52 &#181;M, which also showed no significant difference compared to the control group.</p><p><xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>D shows a statistically significant difference between PBMCs isolated from blood and those from FIP fluid. PBMCs from FIP fluid exhibited a higher level of cellular inflammation compared to those from blood. However, when comparing PBMCs isolated from blood and stimulated with LPS to PBMCs from FIP fluid, no significant difference was found (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>D). This statistical analysis confirms that PBMCs isolated from FIP fluid are true inflammatory responses. These results indicate that, since there is no significant difference between PBMCs isolated from blood stimulated with LPS and PBMCs from FIP fluid, the latter are naturally inflamed [<xref rid="B23-vetsci-12-00847" ref-type="bibr">23</xref>]. In the experimental groups treated with dexamethasone (positive control) and the extract of <italic toggle="yes">P. indusiatus</italic>, a statistically significant difference was observed. PBMCs isolated from blood showed a reduction in nitrite production in both the positive control group and the group treated with <italic toggle="yes">P. indusiatus</italic> extract. However, PBMCs isolated from FIP fluid did not exhibit a reduction in nitrite production.</p></sec><sec id="sec3dot7-vetsci-12-00847"><title>3.7. Phytochemical Composition and Literature Support for Anti-Inflammatory Activity</title><p>In this study, a crude extract of <italic toggle="yes">P. indusiatus</italic> was prepared following the extraction protocol described by Theeraraksakul, K. et al., 2023 [<xref rid="B21-vetsci-12-00847" ref-type="bibr">21</xref>]. Phytochemical analysis confirmed the presence of key anti-inflammatory constituents, including phenolic compounds, flavonoids, and tannins. The extract demonstrated inhibitory effects on the production of nitric oxide (NO), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-&#945;). Furthermore, their study reported that the crude extract of <italic toggle="yes">P. indusiatus</italic> also contained various bioactive compounds, such as catechins, flavonoids, polysaccharides, monosaccharides, mucopolysaccharides, allantoin, alkaloids, epicatechin, gallic acid, caffeic acid, and other polyphenolic compounds are also important contributors to the anti-inflammatory activity of the extract [<xref rid="B24-vetsci-12-00847" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00847" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-12-00847" ref-type="bibr">26</xref>]. Although the crude extract of <italic toggle="yes">P. indusiatus</italic> has not been previously evaluated for its anti-inflammatory effects in cat PBMCs, previous studies have identified bioactive compounds within the extract that possess anti-inflammatory properties. In this study, the observed reduction in NO production in LPS-stimulated PBMCs isolated from healthy cats serves as an important in vitro model (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>B). These findings provide a basis for the future development of anti-inflammatory strategies targeting monocytes and macrophages infected with the FIP virus (<xref rid="vetsci-12-00847-t001" ref-type="table">Table 1</xref>).</p><fig position="anchor" id="vetsci-12-00847-f007" orientation="portrait"><label>Figure 7</label><caption><p>The effect of LPS on nitrite production in stimulated PBMCs was quantified after 24 h of exposure to LPS at concentrations of 0.001, 0.01, 0.1, and 1 &#181;g/mL (<bold>A</bold>). The effect of 19 &#181;g/mL <italic toggle="yes">P. indusiatus</italic> and 5 &#181;g/mL dexamethasone (Dex) on nitrite production in stimulated PBMCs isolated from whole blood of donor cats was quantified after 24 h. The data are presented as mean &#177; SEM, comparing the mean of each column with the means of every other column (<italic toggle="yes">n</italic> = 8) (<bold>B</bold>). The stimulation and suppression of inflammation in PBMCs isolated from FIP fluid using <italic toggle="yes">P. indusiatus</italic> extract (<italic toggle="yes">n</italic> = 5) (<bold>C</bold>). There was analysis by one-way ANOVA; <italic toggle="yes">p</italic> &lt; 0.05 reveals statistically significant differences. The difference in response to treatments between PBMCs isolated from whole blood and those from FIP fluid was analyzed using two-way ANOVA (<italic toggle="yes">p</italic> &lt; 0.05) (<italic toggle="yes">n</italic> = 4) (<bold>D</bold>). **** <italic toggle="yes">p</italic> &lt; 0.0001.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g007.jpg"/></fig><table-wrap position="anchor" id="vetsci-12-00847-t001" orientation="portrait"><object-id pub-id-type="pii">vetsci-12-00847-t001_Table 1</object-id><label>Table 1</label><caption><p>Pharmacological results of <italic toggle="yes">P. indusiatus</italic> efficacy from in vitro studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Preparation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Bioactive Compound</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Experimental Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Key Findings</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extract, hot water, and ethanol.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenolics, flavonoids, and tannins.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Murine macrophages used to study the anti-inflammatory effects of LPS stimulation.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The anti-inflammatory activity was demonstrated by a reduction in the level of released nitric oxide (NO).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Theeraraksakul, K. et al., 2023<break/>[<xref rid="B21-vetsci-12-00847" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crude extract, peel and green mixture, core, and whole mushroom.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Catechins, flavonoids, polysaccharides, monosaccharides, mucopolysaccharides, allantoin, alkaloids, polyphenolic compounds, epicatechin, gallic acid, and caffeic acid.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The experiment was conducted using LPS-induced RAW 264.7 macrophages.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The anti-inflammatory activity was demonstrated by the inhibition of NO, IL-1&#946;, IL-6, and TNF-&#945; secretion.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ruksiriwanich, W. et al., 2022.,<break/>Nazir, Y., et al. 2021., <break/>Sedtananun, S. et al., 2025<break/>[<xref rid="B24-vetsci-12-00847" ref-type="bibr">24</xref>,<xref rid="B25-vetsci-12-00847" ref-type="bibr">25</xref>,<xref rid="B26-vetsci-12-00847" ref-type="bibr">26</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hot water extract of crude polysaccharide from mushroom fruiting body.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polysaccharides.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colitis was induced in mice using dextran sulfate sodium (DSS).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduced the expression of inducible iNOS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Kanwal, S. et al., 2020<break/>[<xref rid="B27-vetsci-12-00847" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">This study utilized an ethanolic extract derived from the whole mushroom.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phenolics, flavonoids, and tannins. [<xref rid="B21-vetsci-12-00847" ref-type="bibr">21</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBMCs from healthy cats were stimulated with LPS and PBMCs from FIP fluid </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The anti-inflammatory activity was demonstrated by the inhibition of NO in PBMCs isolated from healthy cats.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hlaoperm, C. et al.</td></tr></tbody></table></table-wrap><p>Bioactive compounds from <italic toggle="yes">P. indusiatus</italic> demonstrate biochemical and cellular mechanisms of action, ranging from general antioxidant and anti-inflammatory effects to the modulation of specific signaling pathways [<xref rid="B7-vetsci-12-00847" ref-type="bibr">7</xref>]. Therefore, based on the findings of this study and prior research, there is compelling evidence that extracts from <italic toggle="yes">P. indusiatus</italic> possess anti-inflammatory properties and may modulate the immune response, potentially contributing to the inhibition of FIPV in cats.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00847"><title>4. Discussion</title><p>In this study, the FIPV M<sup>pro</sup> had a size of 34 kDa, which increased to 37.2 kDa after the addition of a 10 &#215; His tag and a TEV cleavage site at the N-terminus. The FIPV M<sup>pro</sup> protein was induced by IPTG and analyzed both quantitatively and qualitatively (<xref rid="vetsci-12-00847-f002" ref-type="fig">Figure 2</xref>A). Notably, the FIPV M<sup>pro</sup> comparable in size to the SARS-CoV-2 M<sup>pro</sup>, which has a molecular weight of approximately 33 kDa [<xref rid="B28-vetsci-12-00847" ref-type="bibr">28</xref>]. These findings indicate that the research was successful at this stage.</p><p>The present study revealed a significant finding: the mushroom extract demonstrated FIPV protease inhibition at 69.2%, indicating its potential as a natural source of antiviral compounds. This activity is slightly lower than both ritonavir (71.88%) and lopinavir (84.13%), both of which are established broad-spectrum protease inhibitors clinically used in Human Immunodeficiency Virus (HIV) therapy [<xref rid="B29-vetsci-12-00847" ref-type="bibr">29</xref>] (<xref rid="vetsci-12-00847-f003" ref-type="fig">Figure 3</xref>). These agents have also been shown to inhibit SARS-CoV by strongly binding to its M<sup>pro</sup> [<xref rid="B30-vetsci-12-00847" ref-type="bibr">30</xref>,<xref rid="B31-vetsci-12-00847" ref-type="bibr">31</xref>]. In our study, they served as general protease inhibitory benchmarks, since they are not used for treating FIP. It is important to note that this protease inhibition mechanism differs from that of currently used FIP treatments such as molnupiravir or GS-441524, which primarily target the viral RNA-dependent RNA polymerase (RdRp), and are therefore not appropriate controls for a protease inhibition assay [<xref rid="B32-vetsci-12-00847" ref-type="bibr">32</xref>,<xref rid="B33-vetsci-12-00847" ref-type="bibr">33</xref>]. The absence of GC376, a highly specific FIPV M<sup>pro</sup> inhibitor [<xref rid="B34-vetsci-12-00847" ref-type="bibr">34</xref>,<xref rid="B35-vetsci-12-00847" ref-type="bibr">35</xref>], was due to its unavailability in our laboratory at the time of the study.</p><p>The experimental results revealed that <italic toggle="yes">P. indusiatus</italic> at a concentration of 10 &#181;g/mL achieved the highest inhibition of FIPV M<sup>pro</sup> activity among the tested mushroom extracts, with an inhibition rate of 69.2% (<xref rid="vetsci-12-00847-f003" ref-type="fig">Figure 3</xref>). Despite the mushroom extract&#8217;s inhibition rate being marginally lower than ritonavir and lopinavir, its efficacy as a natural extract warrants further investigation, suggesting the presence of bioactive molecules with FIPV M<sup>pro</sup> inhibitory properties. This finding is particularly relevant because, while current gold standard FIP treatments focus on RdRp, viral proteases (specifically M<sup>pro</sup> or 3CL<sup>pro</sup>) represent an equally critical and well-validated drug target for coronaviruses due to their essential role in processing polyproteins translated from viral RNA [<xref rid="B35-vetsci-12-00847" ref-type="bibr">35</xref>,<xref rid="B36-vetsci-12-00847" ref-type="bibr">36</xref>,<xref rid="B37-vetsci-12-00847" ref-type="bibr">37</xref>]. This enzyme is indispensable for viral polyprotein processing, which is a fundamental step for replication [<xref rid="B37-vetsci-12-00847" ref-type="bibr">37</xref>,<xref rid="B38-vetsci-12-00847" ref-type="bibr">38</xref>]. The success of protease inhibitors in other viral infections (e.g., Human HIV and Hepatitis C virus [HCV]), along with the promising results of FIPV-specific protease inhibitors such as GC376, underscores the druggability of this enzyme [<xref rid="B39-vetsci-12-00847" ref-type="bibr">39</xref>]. Also, due to the high conservation of M<sup>pro</sup> during viral mutagenesis and its critical role in the coronavirus life cycle, M<sup>pro</sup> is considered as a pivotal target for antivirus drug development [<xref rid="B16-vetsci-12-00847" ref-type="bibr">16</xref>]</p><p>Mushroom extracts are widely recognized for their antiviral and anti-inflammatory properties [<xref rid="B40-vetsci-12-00847" ref-type="bibr">40</xref>,<xref rid="B41-vetsci-12-00847" ref-type="bibr">41</xref>]. Previous studies have shown that polysaccharides and adenosine from crude mushroom extract inhibited SARS-CoV protein expression, genomic RNA synthesis, and spike protein activity [<xref rid="B42-vetsci-12-00847" ref-type="bibr">42</xref>,<xref rid="B43-vetsci-12-00847" ref-type="bibr">43</xref>,<xref rid="B44-vetsci-12-00847" ref-type="bibr">44</xref>]. El-Mekkawy, Sahar et al. (1998) have reported that triterpenes extracted from the fruiting bodies of <italic toggle="yes">Ganoderma lucidum</italic> can inhibit the essential protease enzyme of HIV-1 at a concentration of 7.8 &#181;g/mL [<xref rid="B45-vetsci-12-00847" ref-type="bibr">45</xref>]. The findings of this study are consistent with previous reports. The crude extract from <italic toggle="yes">P. indusiatus</italic> is particularly noteworthy for further investigation of its anti-inflammatory properties, as it demonstrated the highest enzyme inhibition among the tested mushroom species and also showed potential for inhibiting the FIPV M<sup>pro</sup>. Exploring protease inhibitors from diverse natural sources, such as mushroom extracts, represents a vital strategy&#8212;offering novel compounds, alternative mechanisms to combat resistance, and a foundation for future combination therapies. Therefore, in this study, the crude extract from <italic toggle="yes">P. indusiatus</italic> was selected for testing its anti-inflammatory effects on PBMCs of donor cats and FIP fluid.</p><p>The PBMCs isolated from both the whole blood of donor cats and FIP fluid, characterized by monocytes and macrophages, are essential components of the innate immune system [<xref rid="B46-vetsci-12-00847" ref-type="bibr">46</xref>,<xref rid="B47-vetsci-12-00847" ref-type="bibr">47</xref>,<xref rid="B48-vetsci-12-00847" ref-type="bibr">48</xref>]. The selection of samples should prioritize PBMCs that are already isolated, do not clump, and exhibit a round, glossy appearance (<xref rid="vetsci-12-00847-f004" ref-type="fig">Figure 4</xref>). The HIV/AIDS Network Coordination Standard Operating Procedure (HANC-SOP) recommends limiting the processing time to a maximum of 8 h [<xref rid="B49-vetsci-12-00847" ref-type="bibr">49</xref>]. Delays exceeding 24 h have been associated with decreased cell viability [<xref rid="B22-vetsci-12-00847" ref-type="bibr">22</xref>]. However, in this study, PBMCs were successfully separated from both whole blood and FIP fluid and tested within 24 h (<xref rid="vetsci-12-00847-f005" ref-type="fig">Figure 5</xref>).</p><p>In the present study, we employed LPS to activate PBMCs as a model of inflammation. LPS, commonly referred to as endotoxin, is a potent pathogen-associated molecular pattern (PAMP) derived from the outer membrane of Gram-negative bacteria. It is recognized primarily by Toll-like receptor 4 (TLR4) expressed on the surface of immune cells, including monocytes/macrophages [<xref rid="B50-vetsci-12-00847" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-12-00847" ref-type="bibr">51</xref>]. Engagement of TLR4 by LPS initiates downstream signaling cascades, notably the myeloid differentiation primary response 88 (MyD88)-dependent pathway, culminating in the activation of key transcription factors such as NF-&#954;B and activator protein 1 (AP-1) [<xref rid="B9-vetsci-12-00847" ref-type="bibr">9</xref>,<xref rid="B50-vetsci-12-00847" ref-type="bibr">50</xref>,<xref rid="B52-vetsci-12-00847" ref-type="bibr">52</xref>,<xref rid="B53-vetsci-12-00847" ref-type="bibr">53</xref>]. Although FIPV is not a bacterial pathogen, viruses similarly trigger innate immune responses by expressing PAMPs, such as double-stranded RNA (dsRNA) and specific viral proteins [<xref rid="B54-vetsci-12-00847" ref-type="bibr">54</xref>]. These are recognized by pattern recognition receptors (PRRs), including endosomal Toll-like receptors (TLRs), such as TLR3, TLR7, TLR8, and TLR9, as well as cytosolic sensors like retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) [<xref rid="B55-vetsci-12-00847" ref-type="bibr">55</xref>,<xref rid="B56-vetsci-12-00847" ref-type="bibr">56</xref>]. Activation of these receptors initiates similar signaling pathways that converge on the activation of transcription factors NF-&#954;B and AP-1 [<xref rid="B10-vetsci-12-00847" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00847" ref-type="bibr">11</xref>] (<xref rid="vetsci-12-00847-f001" ref-type="fig">Figure 1</xref>). Although LPS was used as an inflammatory stimulant in this study, mimicking viral infection in feline PBMCs remains challenging due to the lack of a suitable viral culture system in our lab. Nevertheless, both LPS (via TLR4) and viral components (via other TLRs or cytosolic receptors) activate key pro-inflammatory pathways, particularly NF-&#954;B and AP-1. This results in the upregulation of mediators such as TNF-&#945;, IL-1&#946;, IL-6, and iNOS, supporting the use of LPS as a relevant initial model for evaluating general anti-inflammatory effects.</p><p>The innate immune system&#8217;s ability to initiate responses to LPS was also examined [<xref rid="B57-vetsci-12-00847" ref-type="bibr">57</xref>]. In this report, 0.001, 0.01, 0.1, and 1 &#181;g/mL of LPS were used to stimulate PBMCs isolated from whole blood of donor cats, compared with the absence of LPS (<xref rid="vetsci-12-00847-f006" ref-type="fig">Figure 6</xref>). The data presented in this publication indicate that LPS increased cell viability by approximately 98&#8211;99% within 24 h, correlating with the report by Jansky et al. (2003) [<xref rid="B58-vetsci-12-00847" ref-type="bibr">58</xref>]. A study reported that LPS stimulation increased PBMCs proliferation by activating monocytes and T lymphocytes, thereby promoting their proliferation [<xref rid="B59-vetsci-12-00847" ref-type="bibr">59</xref>,<xref rid="B60-vetsci-12-00847" ref-type="bibr">60</xref>,<xref rid="B61-vetsci-12-00847" ref-type="bibr">61</xref>]. Based on the study results, LPS may have the potential to increase the number of PBMCs [<xref rid="B59-vetsci-12-00847" ref-type="bibr">59</xref>,<xref rid="B60-vetsci-12-00847" ref-type="bibr">60</xref>,<xref rid="B61-vetsci-12-00847" ref-type="bibr">61</xref>]. However, PBMCs isolated from FIP fluid do not exhibit LPS-induced inflammatory responses, likely because virus-infected cats already present with systemic leukocyte activation [<xref rid="B23-vetsci-12-00847" ref-type="bibr">23</xref>]. This diminished responsiveness may be attributed to the fact that FIPV specifically targets monocytes and macrophages, leading to their functional dysregulation [<xref rid="B62-vetsci-12-00847" ref-type="bibr">62</xref>,<xref rid="B63-vetsci-12-00847" ref-type="bibr">63</xref>].</p><p>The effect of <italic toggle="yes">P. indusiatus</italic> on nitrite scavenging activity in LPS-stimulated PBMCs was assessed. During the inflammatory response, nitric oxide production, measured as nitrite levels in the PBMCs&#8217; supernatant, can be upregulated in freshly isolated PBMCs by in vitro stimulation with LPS [<xref rid="B64-vetsci-12-00847" ref-type="bibr">64</xref>,<xref rid="B65-vetsci-12-00847" ref-type="bibr">65</xref>,<xref rid="B66-vetsci-12-00847" ref-type="bibr">66</xref>,<xref rid="B67-vetsci-12-00847" ref-type="bibr">67</xref>,<xref rid="B68-vetsci-12-00847" ref-type="bibr">68</xref>]. LPS triggers the TLR4 pathway, leading to the activation of NF-&#954;B and the upregulation of iNOS [<xref rid="B50-vetsci-12-00847" ref-type="bibr">50</xref>,<xref rid="B51-vetsci-12-00847" ref-type="bibr">51</xref>]. In LPS-induced samples, monocytes/macrophages are the primary NO producers (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>A) [<xref rid="B50-vetsci-12-00847" ref-type="bibr">50</xref>,<xref rid="B52-vetsci-12-00847" ref-type="bibr">52</xref>]. In this study, a group of PBMCs, isolated from donor cat whole blood and stimulated with 1 &#181;g/mL LPS, was evaluated for its anti-inflammatory effects, with a reduction in nitrite serving as an indicator [<xref rid="B68-vetsci-12-00847" ref-type="bibr">68</xref>]. The crude extract of <italic toggle="yes">P. indusiatus</italic> may possess potential anti-inflammatory properties (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>B).</p><p>The test on the reduction of nitrite production by PBMCs isolated from FIP fluid (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>D) clearly demonstrates that cats suffering from this disease naturally exhibit PBMC inflammation, even in the absence of LPS stimulation. The PRRs, such as TLR3, TLR7, RIG-I, and MDA5, lead to IFN signaling [<xref rid="B69-vetsci-12-00847" ref-type="bibr">69</xref>]. This may trigger IFN responses (IFN-&#945;, IFN-&#946;, IFN-&#947;), which can either promote NO production or have other immune effects [<xref rid="B54-vetsci-12-00847" ref-type="bibr">54</xref>]. The host&#8217;s recognition of viral DNA initiates multiple signal transduction pathways that converge on iNOS upregulation, leading to increased endogenous NO production [<xref rid="B70-vetsci-12-00847" ref-type="bibr">70</xref>]. The oxidative degradation of NO results in the formation of its breakdown products, nitrate and nitrite. This process, primarily identified in macrophages, involves the expression of the inducible iNOS enzyme [<xref rid="B71-vetsci-12-00847" ref-type="bibr">71</xref>,<xref rid="B72-vetsci-12-00847" ref-type="bibr">72</xref>]. Consequently, nitrite levels are significantly higher in PBMCs isolated from FIP fluid compared to those from the whole blood of healthy cats, with a statistically significant difference. This aligns with the research conducted by &#214;zbek et al. (2022), which investigated serum nitric oxide levels in cats affected by FIP [<xref rid="B73-vetsci-12-00847" ref-type="bibr">73</xref>]. This elevation in nitrite serves as a reliable indicator of inflammation (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>D) [<xref rid="B74-vetsci-12-00847" ref-type="bibr">74</xref>,<xref rid="B75-vetsci-12-00847" ref-type="bibr">75</xref>].</p><p>The results of this study show a statistically significant difference in the response to treatments between PBMCs isolated from whole blood and those from FIP fluid. PBMCs from whole blood responded to both treatments (dexamethasone and <italic toggle="yes">P. indusiatus</italic> extract) by reducing nitrite production, indicating potential anti-inflammatory effects. However, PBMCs from FIP fluid (possibly from an inflamed environment) did not respond in the same way (<xref rid="vetsci-12-00847-f007" ref-type="fig">Figure 7</xref>C,D). The lack of anti-inflammatory effects from both the mushroom extract and dexamethasone in PBMCs from FIP-affected cats underscores the complex and severe nature of FIP-associated inflammation [<xref rid="B23-vetsci-12-00847" ref-type="bibr">23</xref>,<xref rid="B54-vetsci-12-00847" ref-type="bibr">54</xref>,<xref rid="B62-vetsci-12-00847" ref-type="bibr">62</xref>,<xref rid="B63-vetsci-12-00847" ref-type="bibr">63</xref>,<xref rid="B69-vetsci-12-00847" ref-type="bibr">69</xref>]. Unlike the acute response induced by LPS, FIP involves chronic, systemic inflammation driven by persistent viral replication in macrophages and a dysregulated immune response, characterized by persistently elevated levels of various inflammatory mediators (a systemic cytokine storm) [<xref rid="B52-vetsci-12-00847" ref-type="bibr">52</xref>,<xref rid="B57-vetsci-12-00847" ref-type="bibr">57</xref>,<xref rid="B76-vetsci-12-00847" ref-type="bibr">76</xref>,<xref rid="B77-vetsci-12-00847" ref-type="bibr">77</xref>]. In this hyper-inflammatory state, NO production may be maximally upregulated and &#8220;locked in&#8221;, reducing responsiveness to conventional treatments, including dexamethasone [<xref rid="B54-vetsci-12-00847" ref-type="bibr">54</xref>,<xref rid="B55-vetsci-12-00847" ref-type="bibr">55</xref>,<xref rid="B56-vetsci-12-00847" ref-type="bibr">56</xref>]. This suggests that FIP-related inflammation may involve distinct or more resistant pathways, as well as nitric oxide production through multiple mechanisms, compared to LPS models [<xref rid="B10-vetsci-12-00847" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00847" ref-type="bibr">11</xref>,<xref rid="B54-vetsci-12-00847" ref-type="bibr">54</xref>,<xref rid="B56-vetsci-12-00847" ref-type="bibr">56</xref>]. Additionally, the direct presence PBMCs from FIP fluid may alter cellular signaling compared to LPS-stimulated healthy PBMCs, potentially affecting drug responsiveness. The previous study suggests that dexamethasone has direct anti-inflammatory effects, acting by altering gene transcription&#8212;upregulating anti-inflammatory genes (e.g., IL-10), downregulating pro-inflammatory ones (e.g., IL-6, TNF-&#945;, COX-2, iNOS), and inhibiting the NF-&#954;B pathway [<xref rid="B78-vetsci-12-00847" ref-type="bibr">78</xref>,<xref rid="B79-vetsci-12-00847" ref-type="bibr">79</xref>]. In contrast, <italic toggle="yes">P. indusiatus</italic> modulates immunity and oxidative stress through compounds like &#946;-glucans, which stimulate TNF-&#945;, IL-6, and IL-10 to restore immune balance [<xref rid="B7-vetsci-12-00847" ref-type="bibr">7</xref>,<xref rid="B80-vetsci-12-00847" ref-type="bibr">80</xref>]. While dexamethasone suppresses NF-&#954;B, <italic toggle="yes">P. indusiatus</italic> fine-tunes it to regulate immune responses [<xref rid="B81-vetsci-12-00847" ref-type="bibr">81</xref>,<xref rid="B82-vetsci-12-00847" ref-type="bibr">82</xref>].</p><p>Limitations of this study include, firstly, the use of LPS as a model of a general inflammatory stimulus instead of direct FIPV infection. Although both can activate similar inflammatory pathways (e.g., NF-&#954;B leading to TNF-&#945;, IL-1&#946;, IL-6, and iNOS expression). FIPV infection is more complex, involving intricate virus&#8211;host interactions that LPS cannot fully mimic. Secondly, attempts to develop an in vitro FIPV infection model were unsuccessful. Although efforts were made to establish an FIPV infection model by infecting CRFK (Crandell-Rees Feline Kidney) cells in vitro, these attempts failed due to challenges in isolating the virus from FIP fluid samples, difficulties in quantifying viral load, and the inconsistency of infection. As a result of these limitations, it was not possible to use the actual virus in the study, making it necessary to rely on the LPS-based simulation system, which may not fully reflect the true nature of FIPV infection.</p><p>Future investigations may consider employing alternative approaches to better mimic the natural course of FIPV infection. For example, pseudotyped viral systems expressing the FIPV spike protein could provide a safe and controllable platform for examining viral entry and replication, while FIPV-infected cell lines may offer a more physiologically relevant model for studying virus&#8211;host interactions [<xref rid="B83-vetsci-12-00847" ref-type="bibr">83</xref>,<xref rid="B84-vetsci-12-00847" ref-type="bibr">84</xref>]. Although these models are not without limitations, they could complement the LPS-based stimulation system used in this study and thereby provide a more comprehensive evaluation of the antiviral and anti-inflammatory potential of the tested extracts.</p><p>Despite this, this study represents the first preliminary investigation to evaluate extracts from the mushroom <italic toggle="yes">P. indusiatus</italic> for both anti-FIPV M<sup>pro</sup> activity and anti-inflammatory effects. It also represents the first assessment of the extract&#8217;s effects on PBMCs isolated from FIP fluid compared to PBMCs from healthy donors. The extract demonstrated strong inhibitory effects on FIPV M<sup>pro</sup>. Based on these results, this study is considered successful and has provided important and useful information, opening opportunities for developing new compounds, alternative mechanisms to overcome resistance, and serving as a foundation for future combination therapy research.</p><p>Future research should focus on elucidating the roles of pro-inflammatory cytokines (e.g., IL-6, TNF-&#945;) and other relevant inflammatory mediators involved in the pathogenesis of FIP. Bioactive constituents from <italic toggle="yes">P. indusiatus</italic> should be investigated, and their chemical structures elucidated using advanced analytical techniques (e.g., liquid chromatography&#8211;mass spectrometry; LC-MS/MS). Subsequent evaluations should include both in vitro and in vivo studies to determine the pharmacological properties of the isolated compounds. Initial in vitro assays should assess antiviral efficacy and anti-inflammatory activity in relevant cell-based models. Promising compounds should then undergo in vivo validation using appropriate animal models. Additionally, comparative analyses with currently available FIPV-specific therapeutics are recommended to benchmark their relative efficacy and therapeutic potential.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00847"><title>5. Conclusions</title><p>This study provides compelling preliminary evidence for the dual antiviral and anti-inflammatory potential of <italic toggle="yes">P. indusiatus</italic> extract in the context of FIP. The extract showed a strong inhibitory effect (69.2%) on the FIPV M<sup>pro</sup>, comparable to established protease inhibitors such as ritonavir and lopinavir. It also significantly reduced NO production in LPS-stimulated PBMCs from healthy cats, indicating potent anti-inflammatory activity. Importantly, the extract was also tested on PBMCs isolated from FIP fluid, which are characterized by chronic inflammation and immune dysregulation. However, these cells showed limited responsiveness (nonresponse) to both dexamethasone and <italic toggle="yes">P. indusiatus</italic> extract, underscoring the complexity of immune activation in FIP. Although LPS was used as a surrogate inflammatory stimulus and a direct FIPV infection model was not available, this is the first study to evaluate <italic toggle="yes">P. indusiatus</italic> for both antiviral and anti-inflammatory effects in the context of FIP. These findings highlight the potential of <italic toggle="yes">P. indusiatus</italic> as a natural source of immunomodulatory agents. Future research should focus on isolating its active compounds, elucidating their mechanisms in relevant infection models, and evaluating their therapeutic potential in vivo, including direct comparisons with FIPV-specific inhibitors.</p></sec></body><back><ack><title>Acknowledgments</title><p>I would like to thank Somruedee Sommart, a veterinary nurse at the Kasetsart University Veterinary Teaching Hospital, for collecting whole blood from donors. I am also grateful to the staff the feline clinic, blood bank unit, emergency room, outpatient department (OPD), and Central Lab at the Kasetsart University Veterinary Teaching Hospital, Faculty of Veterinary Medicine, Kasetsart University, Bangkhen Campus for granting access to the data. Additionally, I extend my gratitude to Nuttanit Jirapanth, a veterinary nurse at the Faculty of Veterinary Medicine, Kasetsart University, for her collaboration with The Nine Animal Hospital and M.J. Animal Hospital in screening and selecting FIP fluid samples.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00847"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/vetsci12090847/s1">https://www.mdpi.com/article/10.3390/vetsci12090847/s1</uri>, Figure S1: The appropriate concentration of DMSO for the viability of PBMCs., and Table S1: Optimization of <italic toggle="yes">P. indusiatus</italic> PBMC viability.</p><supplementary-material id="vetsci-12-00847-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="vetsci-12-00847-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, C.H., A.P., K.C., O.R., and J.R.; methodology, C.H., W.M., E.W., and W.K.; software, C.H., E.W., and W.K.; validation, C.H., A.P., O.R., and J.R.; formal analysis, C.H., E.W., and W.K.; investigation, C.H., E.W., and W.K.; resources, A.R., A.P., K.C., O.R., and J.R.; data curation, C.H.; writing&#8212;original draft preparation, C.H.; writing&#8212;review and editing, C.H., W.M., E.W., A.P., K.C., O.R., and J.R.; visualization, C.H., E.W., and W.K.; supervision, A.P., K.C., O.R., and J.R.; project administration, J.R.; funding acquisition, A.P., K.C., and J.R. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by the Ethics Committee of Kasetsart University under protocol number ACKU67-VET-124 and all cat owners provided written consent.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors on request. Further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors confirm that they have no competing interests.</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00847"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>K.</given-names></name></person-group><article-title>Feline infectious peritonitis</article-title><source>Vet. Clin. N. Am. Small Anim. Pract.</source><year>2005</year><volume>35</volume><fpage>39</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.cvsm.2004.10.011</pub-id><pub-id pub-id-type="pmid">15627627</pub-id><pub-id pub-id-type="pmcid">PMC7114919</pub-id></element-citation></ref><ref id="B2-vetsci-12-00847"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Decaro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lanave</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lorusso</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lucente</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Desario</surname><given-names>C.</given-names></name><name name-style="western"><surname>Colaianni</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Elia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferringo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Alfano</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Mutation analysis of the spike protein in Italian feline infectious peritonitis virus and feline enteric coronavirus sequences</article-title><source>Res. Vet. Sci.</source><year>2021</year><volume>135</volume><fpage>15</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.rvsc.2020.12.023</pub-id><pub-id pub-id-type="pmid">33418186</pub-id></element-citation></ref><ref id="B3-vetsci-12-00847"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.S.</given-names></name></person-group><article-title>An updated review of feline coronavirus: Mind the two biotypes</article-title><source>Virus Res.</source><year>2023</year><volume>326</volume><fpage>199059</fpage><pub-id pub-id-type="doi">10.1016/j.virusres.2023.199059</pub-id><pub-id pub-id-type="pmid">36731629</pub-id><pub-id pub-id-type="pmcid">PMC10194308</pub-id></element-citation></ref><ref id="B4-vetsci-12-00847"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Remick</surname><given-names>D.G.</given-names></name></person-group><article-title>Relative cytokine and cytokine inhibitor production by mononuclear cells and neutrophils</article-title><source>Shock</source><year>2003</year><volume>20</volume><fpage>10</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1097/01.shk.0000065704.84144.a4</pub-id><pub-id pub-id-type="pmid">12813362</pub-id></element-citation></ref><ref id="B5-vetsci-12-00847"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Addie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bel&#225;k</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boucraut</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Egberink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frymus</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gruffydd</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hosie</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lloret</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Feline infectious peritonitis: ABCD guidelines on prevention and management</article-title><source>J. Feline Med. Surg.</source><year>2009</year><volume>11</volume><fpage>594</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1016/j.jfms.2009.05.008</pub-id><pub-id pub-id-type="pmid">19481039</pub-id><pub-id pub-id-type="pmcid">PMC7129471</pub-id></element-citation></ref><ref id="B6-vetsci-12-00847"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saylor</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Coggins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Gunn-Moore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jeevaratnam</surname><given-names>K.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stacey</surname><given-names>E.</given-names></name><name name-style="western"><surname>MacFarlane</surname><given-names>L.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020&#8211;2022)</article-title><source>J. Feline Med. Surg.</source><year>2023</year><volume>25</volume><fpage>1098612X231194460</fpage><pub-id pub-id-type="doi">10.1177/1098612x231194460</pub-id><pub-id pub-id-type="pmcid">PMC10812036</pub-id><pub-id pub-id-type="pmid">37732386</pub-id></element-citation></ref><ref id="B7-vetsci-12-00847"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habtemariam</surname><given-names>S.</given-names></name></person-group><article-title>The chemistry, pharmacology and therapeutic potential of the edible mushroom <italic toggle="yes">Dictyophora indusiata</italic> (Vent ex. Pers.) Fischer (syn. <italic toggle="yes">Phallus indusiatus</italic>)</article-title><source>Biomedicines</source><year>2019</year><volume>7</volume><elocation-id>98</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines7040098</pub-id><pub-id pub-id-type="pmid">31842442</pub-id><pub-id pub-id-type="pmcid">PMC6966625</pub-id></element-citation></ref><ref id="B8-vetsci-12-00847"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suleiman</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Younis</surname><given-names>A.M.</given-names></name></person-group><article-title>In vitro assessment of multipotential therapeutic importance of <italic toggle="yes">Hericium erinaceus</italic> mushroom extracts using different solvents</article-title><source>Bioresour. Bioprocess.</source><year>2022</year><volume>9</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s40643-022-00592-6</pub-id><pub-id pub-id-type="pmid">38647811</pub-id><pub-id pub-id-type="pmcid">PMC10991866</pub-id></element-citation></ref><ref id="B9-vetsci-12-00847"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>An examination of the LPS&#8211;TLR4 immune response through the analysis of molecular structures and protein&#8211;protein interactions</article-title><source>Cell Commun. Signal.</source><year>2025</year><volume>23</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.1186/s12964-025-02149-4</pub-id><pub-id pub-id-type="pmid">40102851</pub-id><pub-id pub-id-type="pmcid">PMC11921546</pub-id></element-citation></ref><ref id="B10-vetsci-12-00847"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennessy</surname><given-names>C.</given-names></name><name name-style="western"><surname>McKernan</surname><given-names>D.P.</given-names></name></person-group><article-title>Anti-viral pattern recognition receptors as therapeutic targets</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>2258</elocation-id><pub-id pub-id-type="doi">10.3390/cells10092258</pub-id><pub-id pub-id-type="pmid">34571909</pub-id><pub-id pub-id-type="pmcid">PMC8466445</pub-id></element-citation></ref><ref id="B11-vetsci-12-00847"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>D.</given-names></name><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name></person-group><article-title>Role of pattern recognition receptors in the development of MASLD and potential therapeutic applications</article-title><source>Biomed. Pharmacother.</source><year>2024</year><volume>175</volume><elocation-id>116724</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2024.116724</pub-id><pub-id pub-id-type="pmid">38761424</pub-id></element-citation></ref><ref id="B12-vetsci-12-00847"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.J.</given-names></name></person-group><article-title>Signaling pathways downstream of pattern-recognition receptors and their cross talk</article-title><source>Annu. Rev. Biochem.</source><year>2007</year><volume>76</volume><fpage>447</fpage><lpage>480</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.76.060605.122847</pub-id><pub-id pub-id-type="pmid">17328678</pub-id></element-citation></ref><ref id="B13-vetsci-12-00847"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subedi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Yumnam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.Y.</given-names></name></person-group><article-title>Anti-inflammatory effect of sulforaphane on LPS-activated microglia potentially through JNK/AP-1/NF-&#954;B inhibition and Nrf2/HO-1 activation</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>194</elocation-id><pub-id pub-id-type="doi">10.3390/cells8020194</pub-id><pub-id pub-id-type="pmid">30813369</pub-id><pub-id pub-id-type="pmcid">PMC6406309</pub-id></element-citation></ref><ref id="B14-vetsci-12-00847"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vuong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Arutyunova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lamer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Shields</surname><given-names>J.</given-names></name><name name-style="western"><surname>Saffran</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>McKay</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>van Belkum</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>4282</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-18096-2</pub-id><pub-id pub-id-type="pmid">32855413</pub-id><pub-id pub-id-type="pmcid">PMC7453019</pub-id></element-citation></ref><ref id="B15-vetsci-12-00847"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Citarella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scala</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piperno</surname><given-names>A.</given-names></name><name name-style="western"><surname>Micale</surname><given-names>N.</given-names></name></person-group><article-title>SARS-CoV-2 Mpro: A potential target for peptidomimetics and small-molecule inhibitors</article-title><source>Biomolecules</source><year>2021</year><volume>11</volume><elocation-id>607</elocation-id><pub-id pub-id-type="doi">10.3390/biom11040607</pub-id><pub-id pub-id-type="pmid">33921886</pub-id><pub-id pub-id-type="pmcid">PMC8073203</pub-id></element-citation></ref><ref id="B16-vetsci-12-00847"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Piao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>R.</given-names></name></person-group><article-title>Identifying natural products as feline coronavirus Mpro inhibitors by structure-based virtual screening and enzyme-based assays</article-title><source>ACS Omega</source><year>2025</year><volume>10</volume><fpage>2092</fpage><lpage>2101</lpage><pub-id pub-id-type="doi">10.1021/acsomega.4c08601</pub-id><pub-id pub-id-type="pmid">39866606</pub-id><pub-id pub-id-type="pmcid">PMC11755153</pub-id></element-citation></ref><ref id="B17-vetsci-12-00847"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name></person-group><article-title>Crystallization and preliminary crystallographic study of feline infectious peritonitis virus main protease in complex with an inhibitor</article-title><source>Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun.</source><year>2014</year><volume>70</volume><fpage>1612</fpage><lpage>1615</lpage><pub-id pub-id-type="doi">10.1107/S2053230X14022390</pub-id><pub-id pub-id-type="pmcid">PMC4259223</pub-id><pub-id pub-id-type="pmid">25484209</pub-id></element-citation></ref><ref id="B18-vetsci-12-00847"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moyadee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Roytrakul</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jaresitthikunchai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Phaonakrop</surname><given-names>N.</given-names></name><name name-style="western"><surname>Choowongkomon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ploypetch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tansakul</surname><given-names>N.</given-names></name><name name-style="western"><surname>Rattanasrisomporn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rattanasrisomporn</surname><given-names>J.</given-names></name></person-group><article-title>Serum proteomic approach to identifying differentially expressed proteins in effusive feline infectious peritonitis</article-title><source>Sci. Rep.</source><year>2025</year><volume>15</volume><elocation-id>18899</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-025-03108-2</pub-id><pub-id pub-id-type="pmid">40442209</pub-id><pub-id pub-id-type="pmcid">PMC12122842</pub-id></element-citation></ref><ref id="B19-vetsci-12-00847"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khumtong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rapichai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Saejung</surname><given-names>W.</given-names></name><name name-style="western"><surname>Khamsingnok</surname><given-names>P.</given-names></name><name name-style="western"><surname>Meecharoen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ratanabunyong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>H.V.</given-names></name><name name-style="western"><surname>Tuanthap</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rattanasrisomporn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choowongkomon</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Colorimetric Reverse Transcription Loop-Mediated Isothermal Amplification with Xylenol Orange Targeting Nucleocapsid Gene for Detection of Feline Coronavirus Infection</article-title><source>Viruses</source><year>2025</year><volume>17</volume><elocation-id>418</elocation-id><pub-id pub-id-type="doi">10.3390/v17030418</pub-id><pub-id pub-id-type="pmid">40143345</pub-id><pub-id pub-id-type="pmcid">PMC11946810</pub-id></element-citation></ref><ref id="B20-vetsci-12-00847"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kosukwatthana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rungsuriyawiboon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Rattanasrisomporn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kimram</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tansakul</surname><given-names>N.</given-names></name></person-group><article-title>Cytotoxicity and Immunomodulatory Effects of Cannabidiol on Canine PBMCs: A Study in LPS-Stimulated and Epileptic Dogs</article-title><source>Animals</source><year>2024</year><volume>14</volume><elocation-id>3683</elocation-id><pub-id pub-id-type="doi">10.3390/ani14243683</pub-id><pub-id pub-id-type="pmid">39765588</pub-id><pub-id pub-id-type="pmcid">PMC11672443</pub-id></element-citation></ref><ref id="B21-vetsci-12-00847"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Theeraraksakul</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jaengwang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choowongkomon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tabtimmai</surname><given-names>L.</given-names></name></person-group><article-title>Exploring the biological functions and anti-melanogenesis of <italic toggle="yes">Phallus indusiatus</italic> for mushroom-based cosmetic applications</article-title><source>Cosmetics</source><year>2023</year><volume>10</volume><elocation-id>121</elocation-id><pub-id pub-id-type="doi">10.3390/cosmetics10050121</pub-id></element-citation></ref><ref id="B22-vetsci-12-00847"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stucky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horton</surname><given-names>H.</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>M.J.</given-names></name></person-group><article-title>Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials</article-title><source>J. Immunol. Methods</source><year>2007</year><volume>322</volume><fpage>57</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2007.02.003</pub-id><pub-id pub-id-type="pmid">17382342</pub-id><pub-id pub-id-type="pmcid">PMC1904432</pub-id></element-citation></ref><ref id="B23-vetsci-12-00847"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Stucky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Horton</surname><given-names>H.</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>M.J.</given-names></name></person-group><article-title>Study of Macrophage Activity in Cats with FIP and Naturally FCoV-Shedding Healthy Cats</article-title><source>Pathogens</source><year>2024</year><volume>13</volume><fpage>437</fpage><pub-id pub-id-type="pmid">38921735</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens13060437</pub-id><pub-id pub-id-type="pmcid">PMC11206276</pub-id></element-citation></ref><ref id="B24-vetsci-12-00847"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nazir</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Linsaenkart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khantham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chaitep</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jantrawut</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chittasupho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rachtanapun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jantanasakulwong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phimolsiripol</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sommano</surname><given-names>S.R.</given-names></name><etal/></person-group><article-title>High efficiency in vitro wound healing of <italic toggle="yes">Dictyophora indusiata</italic> extracts via anti-Inflammatory and collagen stimulating (MMP-2 inhibition) mechanisms</article-title><source>J. Fungi.</source><year>2021</year><volume>7</volume><elocation-id>1100</elocation-id><pub-id pub-id-type="doi">10.3390/jof7121100</pub-id><pub-id pub-id-type="pmid">34947082</pub-id><pub-id pub-id-type="pmcid">PMC8708927</pub-id></element-citation></ref><ref id="B25-vetsci-12-00847"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruksiriwanich</surname><given-names>W.</given-names></name><name name-style="western"><surname>Khantham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linsaenkart</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chaitep</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rachtanapun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jantanasakulwong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phimolsiripol</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Re&#382;ek Jambrak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nazir</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yooin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Anti-inflammation of bioactive compounds from ethanolic extracts of edible bamboo mushroom (<italic toggle="yes">Dictyophora indusiata</italic>) as functional health promoting food ingredients</article-title><source>Int. J. Food Sci. Technol.</source><year>2022</year><volume>57</volume><fpage>110</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1111/ijfs.15338</pub-id></element-citation></ref><ref id="B26-vetsci-12-00847"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sedtananun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sujiwattanarat</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hoang Tra</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Suphakun</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seetaha</surname><given-names>S.</given-names></name><name name-style="western"><surname>Auetragul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Choowongkomon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tabtimmai</surname><given-names>L.</given-names></name></person-group><article-title><italic toggle="yes">Phallus indusiatus</italic> Extracts Promoted MCF-7 Apoptosis Under TNF&#945;-induced Tumor Microenvironment by Attenuating NF-kappaB and Akt Activation</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2025</year><volume>26</volume><fpage>479</fpage><pub-id pub-id-type="doi">10.31557/APJCP.2025.26.2.479</pub-id><pub-id pub-id-type="pmid">40022692</pub-id><pub-id pub-id-type="pmcid">PMC12118019</pub-id></element-citation></ref><ref id="B27-vetsci-12-00847"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanwal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Aliya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>S.</given-names></name><name name-style="western"><surname>Saleem</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Nisar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meyiah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Y.</given-names></name></person-group><article-title>Attenuation of DSS induced colitis by <italic toggle="yes">Dictyophora indusiata</italic> polysaccharide (DIP) via modulation of gut microbiota and inflammatory related signaling pathways</article-title><source>J. Funct. Foods</source><year>2020</year><volume>64</volume><fpage>103641</fpage><pub-id pub-id-type="doi">10.1016/j.jff.2019.103641</pub-id></element-citation></ref><ref id="B28-vetsci-12-00847"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name></person-group><article-title>Optimization of the expression of the main protease from SARS-CoV-2</article-title><source>Protein Expr. Purif.</source><year>2023</year><volume>203</volume><fpage>106208</fpage><pub-id pub-id-type="doi">10.1016/j.pep.2022.106208</pub-id><pub-id pub-id-type="pmid">36403706</pub-id><pub-id pub-id-type="pmcid">PMC9673008</pub-id></element-citation></ref><ref id="B29-vetsci-12-00847"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortiz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dejesus</surname><given-names>E.</given-names></name><name name-style="western"><surname>Khanlou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Voronin</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Lunzen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andrade-Villanueva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fourie</surname><given-names>J.</given-names></name><name name-style="western"><surname>De Meyer</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Pauw</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48</article-title><source>AIDS</source><year>2008</year><volume>22</volume><fpage>1389</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e32830285fb</pub-id><pub-id pub-id-type="pmid">18614861</pub-id></element-citation></ref><ref id="B30-vetsci-12-00847"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoergenhofer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stimpfl</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karolyi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zoufaly</surname><given-names>A.</given-names></name></person-group><article-title>Pharmacokinetics of lopinavir and ritonavir in patients hospitalized with coronavirus disease 2019 (COVID-19)</article-title><source>Ann. Intern. Med.</source><year>2020</year><volume>173</volume><fpage>670</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.7326/M20-1550</pub-id><pub-id pub-id-type="pmid">32422065</pub-id><pub-id pub-id-type="pmcid">PMC7236891</pub-id></element-citation></ref><ref id="B31-vetsci-12-00847"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nutho</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mahalapbutr</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hengphasatporn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pattaranggoon</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Simanon</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shigeta</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hannongbua</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rungrotmongkol</surname><given-names>T.</given-names></name></person-group><article-title>Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms</article-title><source>Biochemistry</source><year>2020</year><volume>59</volume><fpage>1769</fpage><lpage>1779</lpage><pub-id pub-id-type="pmid">32293875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1021/acs.biochem.0c00160</pub-id></element-citation></ref><ref id="B32-vetsci-12-00847"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsika</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gallo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fourkiotis</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Argyriou</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Sreeramulu</surname><given-names>S.</given-names></name><name name-style="western"><surname>L&#246;hr</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rogov</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linhard</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gande</surname><given-names>S.L.</given-names></name><etal/></person-group><article-title>Binding adaptation of GS-441524 diversifies Macro domains and downregulates SARS-CoV-2 de-MARylation capacity</article-title><source>J. Mol. Biol.</source><year>2022</year><volume>434</volume><elocation-id>167720</elocation-id><pub-id pub-id-type="doi">10.1016/j.jmb.2022.167720</pub-id><pub-id pub-id-type="pmid">35839840</pub-id><pub-id pub-id-type="pmcid">PMC9284540</pub-id></element-citation></ref><ref id="B33-vetsci-12-00847"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.Q.</given-names></name></person-group><article-title>Oral GS-441524 derivatives: Next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1015355</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1015355</pub-id><pub-id pub-id-type="pmid">36561747</pub-id><pub-id pub-id-type="pmcid">PMC9763260</pub-id></element-citation></ref><ref id="B34-vetsci-12-00847"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perera</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Rathnayake</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Groutas</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name></person-group><article-title>Characterization of amino acid substitutions in feline coronavirus 3C-like protease from a cat with feline infectious peritonitis treated with a protease inhibitor</article-title><source>Vet. Microbiol.</source><year>2019</year><volume>237</volume><elocation-id>108398</elocation-id><pub-id pub-id-type="doi">10.1016/j.vetmic.2019.108398</pub-id><pub-id pub-id-type="pmid">31585653</pub-id><pub-id pub-id-type="pmcid">PMC6779346</pub-id></element-citation></ref><ref id="B35-vetsci-12-00847"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Galasiti Kankanamalage</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Eckstrand</surname><given-names>C.</given-names></name><name name-style="western"><surname>Groutas</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Bannasch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Meadows</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.O.</given-names></name></person-group><article-title>Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis</article-title><source>J. Feline Med. Surg.</source><year>2018</year><volume>20</volume><fpage>378</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1177/1098612X17729626</pub-id><pub-id pub-id-type="pmid">28901812</pub-id><pub-id pub-id-type="pmcid">PMC5871025</pub-id></element-citation></ref><ref id="B36-vetsci-12-00847"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Su</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name></person-group><article-title>What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design</article-title><source>Med. Res. Rev.</source><year>2021</year><volume>41</volume><fpage>1965</fpage><lpage>1998</lpage><pub-id pub-id-type="doi">10.1002/med.21783</pub-id><pub-id pub-id-type="pmid">33460213</pub-id><pub-id pub-id-type="pmcid">PMC8014231</pub-id></element-citation></ref><ref id="B37-vetsci-12-00847"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shyr</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lo</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name></person-group><article-title>Viral proteases as targets for coronavirus disease 2019 drug development</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2021</year><volume>378</volume><fpage>166</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1124/jpet.121.000688</pub-id><pub-id pub-id-type="pmid">33972366</pub-id><pub-id pub-id-type="pmcid">PMC8686716</pub-id></element-citation></ref><ref id="B38-vetsci-12-00847"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abian</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ortega-Alarcon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jimenez-Alesanco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ceballos-Laita</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vega</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reyburn</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Rizzuti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Velazquez-Campoy</surname><given-names>A.</given-names></name></person-group><article-title>Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening</article-title><source>Int. J. Biol. Macromol.</source><year>2020</year><volume>164</volume><fpage>1693</fpage><lpage>1703</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2020.07.235</pub-id><pub-id pub-id-type="pmid">32745548</pub-id><pub-id pub-id-type="pmcid">PMC7395220</pub-id></element-citation></ref><ref id="B39-vetsci-12-00847"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majerov&#225;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Konvalinka</surname><given-names>J.</given-names></name></person-group><article-title>Viral proteases as therapeutic targets</article-title><source>Mol. Aspects Med.</source><year>2022</year><volume>88</volume><fpage>101159</fpage><pub-id pub-id-type="doi">10.1016/j.mam.2022.101159</pub-id><pub-id pub-id-type="pmid">36459838</pub-id><pub-id pub-id-type="pmcid">PMC9706241</pub-id></element-citation></ref><ref id="B40-vetsci-12-00847"><label>40.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Varghese</surname><given-names>R.</given-names></name><name name-style="western"><surname>Efferth</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ramamoorthy</surname><given-names>S.</given-names></name></person-group><article-title>Exploring the anti-COVID-19 potential of mushroom metabolites: Current status and perspectives</article-title><source>Traditional Medicines and Natural Products as Preventive and Therapeutic Agents Against COVID-19</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2025</year><fpage>317</fpage><lpage>337</lpage></element-citation></ref><ref id="B41-vetsci-12-00847"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gopal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muthu</surname><given-names>M.</given-names></name></person-group><article-title>Antioxidant activity of mushroom extracts/polysaccharides&#8212;Their antiviral properties and plausible anti-COVID-19 properties</article-title><source>Antioxidants</source><year>2021</year><volume>10</volume><elocation-id>1899</elocation-id><pub-id pub-id-type="doi">10.3390/antiox10121899</pub-id><pub-id pub-id-type="pmid">34943001</pub-id><pub-id pub-id-type="pmcid">PMC8750169</pub-id></element-citation></ref><ref id="B42-vetsci-12-00847"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J.</given-names></name></person-group><article-title>Medicinal fungi with antiviral effect</article-title><source>Molecules</source><year>2022</year><volume>27</volume><elocation-id>4457</elocation-id><pub-id pub-id-type="doi">10.3390/molecules27144457</pub-id><pub-id pub-id-type="pmid">35889330</pub-id><pub-id pub-id-type="pmcid">PMC9322162</pub-id></element-citation></ref><ref id="B43-vetsci-12-00847"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verma</surname><given-names>A.K.</given-names></name></person-group><article-title>Cordycepin: A bioactive metabolite of Cordyceps militaris and polyadenylation inhibitor with therapeutic potential against Covid-19</article-title><source>J. Biomol. Struct. Dyn.</source><year>2020</year><volume>40</volume><fpage>3745</fpage><lpage>3752</lpage><pub-id pub-id-type="doi">10.1080/07391102.2020.1850352</pub-id><pub-id pub-id-type="pmid">33225826</pub-id><pub-id pub-id-type="pmcid">PMC7754931</pub-id></element-citation></ref><ref id="B44-vetsci-12-00847"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Z.</given-names></name></person-group><article-title>Structural characterization and antiviral activity of a novel heteropolysaccharide isolated from Grifola frondosa against enterovirus 71</article-title><source>Carbohydr Polym.</source><year>2016</year><volume>144</volume><fpage>382</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2015.12.005</pub-id><pub-id pub-id-type="pmid">27083830</pub-id></element-citation></ref><ref id="B45-vetsci-12-00847"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Mekkawy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meselhy</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tezuka</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hattori</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kakiuchi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shimotohno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kawahata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otake</surname><given-names>T.</given-names></name></person-group><article-title>Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum</article-title><source>Phytochemistry</source><year>1998</year><volume>49</volume><fpage>1651</fpage><lpage>1657</lpage><pub-id pub-id-type="doi">10.1016/S0031-9422(98)00254-4</pub-id><pub-id pub-id-type="pmid">9862140</pub-id></element-citation></ref><ref id="B46-vetsci-12-00847"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bienzle</surname><given-names>D.</given-names></name><name name-style="western"><surname>Reggeti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>C.</given-names></name></person-group><article-title>Immunophenotype and functional properties of feline dendritic cells derived from blood and bone marrow</article-title><source>Vet. Immunol. Immunopathol.</source><year>2003</year><volume>96</volume><fpage>19</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S0165-2427(03)00132-6</pub-id><pub-id pub-id-type="pmid">14522131</pub-id></element-citation></ref><ref id="B47-vetsci-12-00847"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parihar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eubank</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Doseff</surname><given-names>A.I.</given-names></name></person-group><article-title>Monocytes and macrophages regulate immunity through dynamic networks of survival and cell death</article-title><source>J. Innate Immun.</source><year>2010</year><volume>2</volume><fpage>204</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1159/000296507</pub-id><pub-id pub-id-type="pmid">20375558</pub-id><pub-id pub-id-type="pmcid">PMC2956013</pub-id></element-citation></ref><ref id="B48-vetsci-12-00847"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Garc&#234;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>C.</given-names></name><name name-style="western"><surname>Neves</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Brito</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Marques</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sousa</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>A.R.</given-names></name><etal/></person-group><article-title>Feline Infectious Peritonitis Effusion Index: A Novel Diagnostic Method and Validation of Flow Cytometry-Based Delta Total Nucleated Cells Analysis on the Sysmex XN-1000V<sup>&#174;</sup></article-title><source>Vet. Sci.</source><year>2024</year><volume>11</volume><elocation-id>563</elocation-id><pub-id pub-id-type="doi">10.3390/vetsci11110563</pub-id><pub-id pub-id-type="pmid">39591337</pub-id><pub-id pub-id-type="pmcid">PMC11598915</pub-id></element-citation></ref><ref id="B49-vetsci-12-00847"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Browne</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Doolan</surname><given-names>D.L.</given-names></name></person-group><article-title>Technical pitfalls when collecting, cryopreserving, thawing, and stimulating human T-cells</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1382192</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1382192</pub-id><pub-id pub-id-type="pmid">38812513</pub-id><pub-id pub-id-type="pmcid">PMC11133553</pub-id></element-citation></ref><ref id="B50-vetsci-12-00847"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jagannath</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.D.</given-names></name><name name-style="western"><surname>Sharafkhaneh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kolodziejska</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Eissa</surname><given-names>N.T.</given-names></name></person-group><article-title>Toll-like receptor 4 is a sensor for autophagy associated with innate immunity</article-title><source>Immunity</source><year>2007</year><volume>27</volume><fpage>135</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2007.05.022</pub-id><pub-id pub-id-type="pmid">17658277</pub-id><pub-id pub-id-type="pmcid">PMC2680670</pub-id></element-citation></ref><ref id="B51-vetsci-12-00847"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oshio</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kawamura</surname><given-names>Y.I.</given-names></name><name name-style="western"><surname>Hagiwara</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mizutani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Okada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Otsubo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Inagaki-Ohara</surname><given-names>K.</given-names></name><name name-style="western"><surname>Matsukawa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haga</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Chemokine receptor CCR8 is required for lipopolysaccharide-triggered cytokine production in mouse peritoneal macrophages</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e94445</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0094445</pub-id><pub-id pub-id-type="pmid">24714157</pub-id><pub-id pub-id-type="pmcid">PMC3979852</pub-id></element-citation></ref><ref id="B52-vetsci-12-00847"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tucureanu</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Rebleanu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Constantinescu</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Deleanu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Voicu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Butoi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Calin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Manduteanu</surname><given-names>I.</given-names></name></person-group><article-title>Lipopolysaccharide-induced inflammation in monocytes/macrophages is blocked by liposomal delivery of Gi-protein inhibitor</article-title><source>Int. J. Nanomed.</source><year>2018</year><volume>13</volume><fpage>63</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2147/IJN.S150918</pub-id><pub-id pub-id-type="pmcid">PMC5743190</pub-id><pub-id pub-id-type="pmid">29317816</pub-id></element-citation></ref><ref id="B53-vetsci-12-00847"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>X.</given-names></name></person-group><article-title>Degraded &#955;-carrageenan activates NF-&#954;B and AP-1 pathways in macrophages and enhances LPS-induced TNF-&#945; secretion through AP-1</article-title><source>Biochim. Biophys. Acta</source><year>2014</year><volume>1840</volume><fpage>2162</fpage><lpage>2170</lpage><pub-id pub-id-type="doi">10.1016/j.bbagen.2014.03.011</pub-id><pub-id pub-id-type="pmid">24641824</pub-id></element-citation></ref><ref id="B54-vetsci-12-00847"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Kurt-Jones</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name></person-group><article-title>Pattern recognition receptors and the innate immune response to viral infection</article-title><source>Viruses</source><year>2011</year><volume>3</volume><elocation-id>920</elocation-id><pub-id pub-id-type="doi">10.3390/v3060920</pub-id><pub-id pub-id-type="pmid">21994762</pub-id><pub-id pub-id-type="pmcid">PMC3186011</pub-id></element-citation></ref><ref id="B55-vetsci-12-00847"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kolli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Velayutham</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Casola</surname><given-names>A.</given-names></name></person-group><article-title>Host-viral interactions: Role of pattern recognition receptors (PRRs) in human pneumovirus infections</article-title><source>Pathogens</source><year>2013</year><volume>2</volume><fpage>232</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.3390/pathogens2020232</pub-id><pub-id pub-id-type="pmid">24244872</pub-id><pub-id pub-id-type="pmcid">PMC3826451</pub-id></element-citation></ref><ref id="B56-vetsci-12-00847"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okamoto</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukamoto</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kouwaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Seya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oshiumi</surname><given-names>H.</given-names></name></person-group><article-title>Recognition of viral RNA by pattern recognition receptors in the induction of innate immunity and excessive inflammation during respiratory viral infections</article-title><source>Viral Immunol.</source><year>2017</year><volume>30</volume><fpage>408</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1089/vim.2016.0178</pub-id><pub-id pub-id-type="pmid">28609250</pub-id></element-citation></ref><ref id="B57-vetsci-12-00847"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ngkelo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meja</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yeadon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Adcock</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kirkham</surname><given-names>P.A.</given-names></name></person-group><article-title>LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and G i &#945; dependent PI-3kinase signalling</article-title><source>J. Inflamm.</source><year>2012</year><volume>9</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1186/1476-9255-9-1</pub-id><pub-id pub-id-type="pmcid">PMC3293082</pub-id><pub-id pub-id-type="pmid">22239975</pub-id></element-citation></ref><ref id="B58-vetsci-12-00847"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reymanova</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kopecky</surname><given-names>J.</given-names></name></person-group><article-title>Dynamics of cytokine production in human peripheral blood mononuclear cells stimulated by LPS, or infected by Borrelia</article-title><source>Physiol. Res.</source><year>2003</year><volume>52</volume><fpage>593</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.33549/physiolres.930372</pub-id><pub-id pub-id-type="pmid">14535835</pub-id></element-citation></ref><ref id="B59-vetsci-12-00847"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name></person-group><article-title>Functional differences and similarities in activated peripheral blood mononuclear cells by lipopolysaccharide or phytohemagglutinin stimulation between human and cynomolgus monkeys</article-title><source>Ann. Transl. Med.</source><year>2021</year><volume>9</volume><fpage>257</fpage><pub-id pub-id-type="doi">10.21037/atm-20-4548</pub-id><pub-id pub-id-type="pmid">33708884</pub-id><pub-id pub-id-type="pmcid">PMC7940909</pub-id></element-citation></ref><ref id="B60-vetsci-12-00847"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kubin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamoun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Trinchieri</surname><given-names>G.</given-names></name></person-group><article-title>Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells</article-title><source>J. Exp. Med.</source><year>1994</year><volume>180</volume><fpage>211</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1084/jem.180.1.211</pub-id><pub-id pub-id-type="pmid">7516408</pub-id><pub-id pub-id-type="pmcid">PMC2191554</pub-id></element-citation></ref><ref id="B61-vetsci-12-00847"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Flad</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Rietschel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mattern</surname><given-names>T.</given-names></name></person-group><article-title>Induction of proliferation and cytokine production in human T lymphocytes by lipopolysaccharide (LPS)</article-title><source>Toxicology</source><year>2000</year><volume>152</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/S0300-483X(00)00290-0</pub-id><pub-id pub-id-type="pmid">11090938</pub-id></element-citation></ref><ref id="B62-vetsci-12-00847"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malbon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Michalopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Meli</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Tasker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baptiste</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kipar</surname><given-names>A.</given-names></name></person-group><article-title>Colony stimulating factors in early feline infectious peritonitis virus infection of monocytes and in end stage feline infectious peritonitis; a combined in vivo and in vitro approach</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>893</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9110893</pub-id><pub-id pub-id-type="pmid">33121170</pub-id><pub-id pub-id-type="pmcid">PMC7692899</pub-id></element-citation></ref><ref id="B63-vetsci-12-00847"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cornelissen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dewerchin</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Van Hamme</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Absence of surface expression of feline infectious peritonitis virus (FIPV) antigens on infected cells isolated from cats with FIP</article-title><source>Vet. Microbiol.</source><year>2007</year><volume>121</volume><fpage>131</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2006.11.026</pub-id><pub-id pub-id-type="pmid">17188823</pub-id><pub-id pub-id-type="pmcid">PMC7127496</pub-id></element-citation></ref><ref id="B64-vetsci-12-00847"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hirano</surname><given-names>T.</given-names></name><name name-style="western"><surname>Matsuda</surname><given-names>T.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Miyasaka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Buchan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maid</surname><given-names>R.</given-names></name><name name-style="western"><surname>Feldmann</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis</article-title><source>Eur. J. Immunol.</source><year>1988</year><volume>18</volume><fpage>1797</fpage><lpage>1802</lpage><pub-id pub-id-type="doi">10.1002/eji.1830181122</pub-id><pub-id pub-id-type="pmid">2462501</pub-id></element-citation></ref><ref id="B65-vetsci-12-00847"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bergroth</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zvaifler</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Firestein</surname><given-names>G.S.</given-names></name></person-group><article-title>Cytokines in chronic inflammatory arthritis. III. Rheumatoid arthritis monocytes are not unusually sensitive to &#947;-interferon, but have defective &#947;-interferon&#8211;mediated HLA&#8211;DQ and HLA&#8211;DR induction</article-title><source>Arthritis Rheum.</source><year>1989</year><volume>32</volume><fpage>1074</fpage><lpage>1079</lpage><pub-id pub-id-type="doi">10.1002/anr.1780320904</pub-id><pub-id pub-id-type="pmid">2505778</pub-id></element-citation></ref><ref id="B66-vetsci-12-00847"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firestein</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Alvaro-Gracia</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Maki</surname><given-names>R.</given-names></name></person-group><article-title>Quantitative analysis of cytokine gene expression in rheumatoid arthritis</article-title><source>J. Immunol.</source><year>1990</year><volume>144</volume><fpage>3347</fpage><lpage>3353</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.144.9.3347</pub-id><pub-id pub-id-type="pmid">2109776</pub-id></element-citation></ref><ref id="B67-vetsci-12-00847"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sakurai</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kohsaka</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Higashiyama</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hirata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kanno</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>I.</given-names></name><name name-style="western"><surname>Miyasaka</surname><given-names>N.</given-names></name></person-group><article-title>Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides</article-title><source>J. Clin. Investig.</source><year>1995</year><volume>96</volume><fpage>2357</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1172/JCI118292</pub-id><pub-id pub-id-type="pmid">7593623</pub-id><pub-id pub-id-type="pmcid">PMC185887</pub-id></element-citation></ref><ref id="B68-vetsci-12-00847"><label>68.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Rocks</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>O&#8217;Shaughnessy</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Perrett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Winyard</surname><given-names>P.G.</given-names></name></person-group><article-title>Analysis of nitrite and nitrate in the study of inflammation</article-title><source>Inflammation Protocols, Methods in Molecular Biology</source><publisher-name>Humana Press</publisher-name><publisher-loc>Totowa, NJ, USA</publisher-loc><year>2003</year><fpage>305</fpage><lpage>320</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1385/1-59259-374-7:305</pub-id><pub-id pub-id-type="pmid">12769498</pub-id></element-citation></ref><ref id="B69-vetsci-12-00847"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Capozza</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pratelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Camero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lanave</surname><given-names>G.</given-names></name><name name-style="western"><surname>Greco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pellegrini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tempesta</surname><given-names>M.</given-names></name></person-group><article-title>Feline coronavirus and alpha-herpesvirus infections: Innate immune response and immune escape mechanisms</article-title><source>Animals</source><year>2021</year><volume>11</volume><elocation-id>3548</elocation-id><pub-id pub-id-type="doi">10.3390/ani11123548</pub-id><pub-id pub-id-type="pmid">34944324</pub-id><pub-id pub-id-type="pmcid">PMC8698202</pub-id></element-citation></ref><ref id="B70-vetsci-12-00847"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garren</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Ashcraft</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Douglass</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brisbois</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Handa</surname><given-names>H.</given-names></name></person-group><article-title>Nitric oxide and viral infection: Recent developments in antiviral therapies and platforms</article-title><source>Appl. Mater. Today</source><year>2021</year><volume>22</volume><fpage>100887</fpage><pub-id pub-id-type="doi">10.1016/j.apmt.2020.100887</pub-id><pub-id pub-id-type="pmid">38620577</pub-id><pub-id pub-id-type="pmcid">PMC7718584</pub-id></element-citation></ref><ref id="B71-vetsci-12-00847"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abdelal</surname><given-names>H.O.</given-names></name></person-group><article-title>Nitric oxide in parasitic infections: A friend or foe?</article-title><source>J. Parasit. Dis.</source><year>2022</year><volume>46</volume><fpage>1147</fpage><lpage>1163</lpage><pub-id pub-id-type="doi">10.1007/s12639-022-01518-x</pub-id><pub-id pub-id-type="pmid">36457767</pub-id><pub-id pub-id-type="pmcid">PMC9606182</pub-id></element-citation></ref><ref id="B72-vetsci-12-00847"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olyslaegers</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dedeurwaerder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Desmarets</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Dewerchin</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Altered expression of adhesion molecules on peripheral blood leukocytes in feline infectious peritonitis</article-title><source>Vet. Microbiol.</source><year>2013</year><volume>166</volume><fpage>438</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2013.06.027</pub-id><pub-id pub-id-type="pmid">23910523</pub-id><pub-id pub-id-type="pmcid">PMC7117481</pub-id></element-citation></ref><ref id="B73-vetsci-12-00847"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#214;zbek</surname><given-names>M.</given-names></name><name name-style="western"><surname>&#214;zkan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kaya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Y&#305;ld&#305;r&#305;m</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kozat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akg&#252;l</surname><given-names>Y.</given-names></name></person-group><article-title>Clinicopathological and biochemical evaluation of Feline Infectious Peritonitis in Turkish Van cats</article-title><source>J. Hell. Vet. Med. Soc.</source><year>2022</year><volume>73</volume><fpage>4379</fpage><lpage>4388</lpage><pub-id pub-id-type="doi">10.12681/jhvms.27159</pub-id></element-citation></ref><ref id="B74-vetsci-12-00847"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waltz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Escobar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Botero</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zuckerbraun</surname><given-names>B.S.</given-names></name></person-group><article-title>Nitrate/nitrite as critical mediators to limit oxidative injury and inflammation</article-title><source>Antioxid. Redox Signal.</source><year>2015</year><volume>23</volume><fpage>328</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1089/ars.2015.6256</pub-id><pub-id pub-id-type="pmid">26140517</pub-id><pub-id pub-id-type="pmcid">PMC4692126</pub-id></element-citation></ref><ref id="B75-vetsci-12-00847"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Fei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.L.</given-names></name></person-group><article-title>Impact of nitrite exposure on plasma biochemical parameters and immune-related responses in Takifugu rubripes</article-title><source>Aquat. Toxicol.</source><year>2020</year><volume>218</volume><fpage>105362</fpage><pub-id pub-id-type="doi">10.1016/j.aquatox.2019.105362</pub-id><pub-id pub-id-type="pmid">31783303</pub-id></element-citation></ref><ref id="B76-vetsci-12-00847"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherding</surname><given-names>R.G.</given-names></name></person-group><article-title>Feline infectious peritonitis (feline coronavirus)</article-title><source>J. Small Anim. Pract.</source><year>2009</year><volume>50</volume><fpage>132</fpage><lpage>143</lpage></element-citation></ref><ref id="B77-vetsci-12-00847"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malbon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Fonfara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Meli</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Hahn</surname><given-names>S.</given-names></name><name name-style="western"><surname>Egberink</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kipar</surname><given-names>A.</given-names></name></person-group><article-title>Feline infectious peritonitis as a systemic inflammatory disease: Contribution of liver and heart to the pathogenesis</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>1144</elocation-id><pub-id pub-id-type="doi">10.3390/v11121144</pub-id><pub-id pub-id-type="pmid">31835559</pub-id><pub-id pub-id-type="pmcid">PMC6949997</pub-id></element-citation></ref><ref id="B78-vetsci-12-00847"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zappia</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Torralba-Agu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Echeverria</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fitzsimons</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Monczor</surname><given-names>F.</given-names></name></person-group><article-title>Antihistamines potentiate dexamethasone anti-inflammatory effects. Impact on glucocorticoid receptor-mediated expression of inflammation-related genes</article-title><source>Cells</source><year>2021</year><volume>10</volume><fpage>3026</fpage><pub-id pub-id-type="pmid">34831249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cells10113026</pub-id><pub-id pub-id-type="pmcid">PMC8617649</pub-id></element-citation></ref><ref id="B79-vetsci-12-00847"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name></person-group><article-title>Update on molecular mechanisms of corticosteroid resistance in chronic obstructive pulmonary disease</article-title><source>Pulm. Pharmacol. Ther.</source><year>2016</year><volume>37</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2016.01.002</pub-id><pub-id pub-id-type="pmid">26805715</pub-id></element-citation></ref><ref id="B80-vetsci-12-00847"><label>80.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>D.</given-names></name><name name-style="western"><surname>Negi</surname><given-names>P.S.</given-names></name></person-group><article-title>Role of mushroom polysaccharides in improving gut health and associated diseases</article-title><source>Microbiome, Immunity, Digestive Health and Nutrition</source><publisher-name>Academic Press</publisher-name><publisher-loc>London, UK</publisher-loc><publisher-name>Elsevier</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2022</year><fpage>431</fpage><lpage>448</lpage></element-citation></ref><ref id="B81-vetsci-12-00847"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thrikawala</surname><given-names>S.U.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Rosowski</surname><given-names>E.E.</given-names></name></person-group><article-title>Glucocorticoids Suppress NF-&#954;B&#8211;Mediated Neutrophil Control of Aspergillus fumigatus Hyphal Growth</article-title><source>J. Immunol.</source><year>2024</year><volume>213</volume><fpage>971</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2400021</pub-id><pub-id pub-id-type="pmid">39178124</pub-id><pub-id pub-id-type="pmcid">PMC11408098</pub-id></element-citation></ref><ref id="B82-vetsci-12-00847"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name></person-group><article-title>New Insights into Chemical Profiles and Health-Promoting Effects of Edible Mushroom <italic toggle="yes">Dictyophora indusiata</italic> (Vent ex. Pers.) Fischer: A Review</article-title><source>J. Fungi.</source><year>2025</year><volume>11</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.3390/jof11010075</pub-id><pub-id pub-id-type="pmcid">PMC11767163</pub-id><pub-id pub-id-type="pmid">39852494</pub-id></element-citation></ref><ref id="B83-vetsci-12-00847"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Optimization and validation of a virus-like particle pseudotyped virus neutralization assay for SARS-CoV-2</article-title><source>MedComm</source><year>2024</year><volume>5</volume><fpage>e615</fpage><pub-id pub-id-type="doi">10.1002/mco2.615</pub-id><pub-id pub-id-type="pmid">38881676</pub-id><pub-id pub-id-type="pmcid">PMC11176738</pub-id></element-citation></ref><ref id="B84-vetsci-12-00847"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name></person-group><article-title>Establishment of replication deficient vesicular stomatitis virus for studies of PEDV spike-mediated cell entry and its inhibition</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>2075</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11082075</pub-id><pub-id pub-id-type="pmid">37630636</pub-id><pub-id pub-id-type="pmcid">PMC10457912</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00847-f001" orientation="portrait"><label>Figure 1</label><caption><p>This figure illustrates the activation of TLR&#8211;NF-&#954;B and AP-1 signaling pathways in response to LPS or viral stimulation, resulting in the upregulation of inducible iNOS, COX-2, PGE2, and pro-inflammatory cytokines. This schematic was adapted from Luo R. et al., 2025, Yu, L. et al., 2024, and Hennessy &amp; McKernan., 2021 [<xref rid="B9-vetsci-12-00847" ref-type="bibr">9</xref>,<xref rid="B10-vetsci-12-00847" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00847" ref-type="bibr">11</xref>].</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g001.jpg"/></fig><fig position="float" id="vetsci-12-00847-f002" orientation="portrait"><label>Figure 2</label><caption><p>Protein purification was performed using a Ni<sup>2+</sup> affinity column, with protein expression induced by 0.4 mM IPTG. The FIPV M<sup>pro</sup> was detected at 37.2 kDa on an SDS-PAGE gel. lane1: Marker, lane2: Pellet FIP, lane3: Supernatant FIP, lane4: Flowthrough, lane5: Wash A, lane6: 20% Buffer B, lane7: 40% Buffer B, lane 8&#8211;9: 60% Buffer B, lane10&#8211;11: 80% Buffer B, lane12&#8211;14: 100% Buffer B (<bold>A</bold>). Western blot analysis confirmed the presence of the FIPV M<sup>pro</sup> protein at 37.20 kDa (<bold>B</bold>). The reaction rates of the FIPV M<sup>pro</sup> enzyme (Relative Fluorescence Units/sec) at enzyme concentrations of 1 and 0.5 &#181;M (<bold>C</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g002.jpg"/></fig><fig position="float" id="vetsci-12-00847-f003" orientation="portrait"><label>Figure 3</label><caption><p>The relationship between the percentage inhibition of FIPV M<sup>pro</sup> (1 &#181;M) and crude mushroom extracts at a concentration of 10 &#181;g/mL was evaluated. The inhibition of FIPV M<sup>pro</sup> enzyme activity was evaluated at a concentration of 1 &#181;M. At a concentration of 10 &#181;g/mL, lopinavir inhibited enzyme activity by 84.13%, while ritonavir inhibited it by 71.88%. <italic toggle="yes">P. indusiatus</italic> exhibited the highest inhibition of FIPV M<sup>pro</sup> activity at 69.2%. The dotted line represents 50% relative inhibition.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g003.jpg"/></fig><fig position="float" id="vetsci-12-00847-f004" orientation="portrait"><label>Figure 4</label><caption><p>Morphological studies by inverted microscope at actual magnification 50 &#181;m on PBMCs. Normal PBMCs without clumping can be observed when isolated from whole blood (<bold>A</bold>). PBMCs isolated from the fluid showed signs of platelet clumping (<bold>B</bold>). PBMCs separated from FIP fluid without clumping are shown in (<bold>C</bold>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g004.jpg"/></fig><fig position="float" id="vetsci-12-00847-f005" orientation="portrait"><label>Figure 5</label><caption><p>The PBMC viability was analyzed by comparing PBMCs from whole blood collection and FIP fluid samples using a two-way ANOVA. The data are presented as mean &#177; SEM for PBMCs viability, comparing each cell mean with the other cell means in the same row (<italic toggle="yes">n</italic> = 5). * <italic toggle="yes">p</italic> &lt; 0.05, PBMCs from FIP fluid vs. PBMCs from blood.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g005.jpg"/></fig><fig position="float" id="vetsci-12-00847-f006" orientation="portrait"><label>Figure 6</label><caption><p>Testing the appropriate concentration of LPS compared to the control group without adding LPS, using concentrations of 0.001, 0.01, 0.1, and 1 &#181;g/mL for 24 h, which were analyzed by one-way ANOVA; * <italic toggle="yes">p</italic> &lt; 0.05 revealed statistically significant differences (<italic toggle="yes">n</italic> = 3).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="vetsci-12-00847-g006.jpg"/></fig></floats-group></article></pmc-articleset>